Cluster	ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
group_G5_1_0	C0007786	Brain Ischemia	12/50	358/21671	2.3752266736143e-11	6.30708932991125e-08	3.34096609039841e-08	BECN1/CEBPB/SGK1/MFN2/RELA/PIK3CB/MAPK3/MAPK14/SRC/NFKB1/BCL2L1/EPAS1	12
group_G5_1_0	C0003130	Anoxia	11/50	287/21671	4.28907808902499e-11	6.30708932991125e-08	3.34096609039841e-08	SGK1/PRKAA1/PMAIP1/PSEN1/MAPK3/MAPK14/SRC/STAT1/NFKB1/BCL2L1/EPAS1	11
group_G5_1_0	C0333516	Tumor necrosis	11/50	350/21671	3.54903267613043e-10	3.47923503349986e-07	1.84300644234142e-07	TFE3/BECN1/RELA/PRKAA1/PSEN1/PIK3CB/STK11/STAT1/NFKB1/NPC1/IKBKB	11
group_G5_1_0	C3714514	Infection	12/50	491/21671	8.89790928738419e-10	4.79013456271447e-07	2.53741088881956e-07	BAG3/HRAS/CEBPB/RELA/PMAIP1/MAP1LC3A/MAPK3/MAPK14/RICTOR/STAT1/NFKB1/BCL2L1	12
group_G5_1_0	C0008479	Chondrosarcoma	11/50	385/21671	9.69105214147685e-10	4.79013456271447e-07	2.53741088881956e-07	BAG3/TFEB/BECN1/PRKAA1/PIK3CB/MAPK3/MAPK14/SRC/BCL2L1/EPAS1/ATG12	11
group_G5_1_0	C0041341	Tuberous Sclerosis	10/50	289/21671	9.77246085558885e-10	4.79013456271447e-07	2.53741088881956e-07	HRAS/TSC1/PRKAA1/PIK3CB/MAPK3/MAPK14/STK11/NFKB1/NPC1/IKBKB	10
group_G5_1_0	C0026918	Mycobacterium Infections	8/50	183/21671	8.79677997597676e-09	3.69590427276395e-06	1.95777960367603e-06	TFEB/OPTN/PIK3CB/MAPK14/STK11/STAT1/IKBKB/DRAM1	8
group_G5_1_0	C1854465	TUBEROUS SCLEROSIS 1 (disorder)	5/50	32/21671	1.02274166222959e-08	3.75985403577151e-06	1.99165481592077e-06	TSC1/PRKAA1/PSEN1/PIK3CB/STK11	5
group_G5_1_0	C0008370	Cholestasis	10/50	420/21671	3.4554697720979e-08	1.12917073330444e-05	5.98139796807589e-06	HRAS/RELA/PRKAA1/PIK3CB/MAPK3/MAPK14/STK11/STAT1/NPC1/EPAS1	10
group_G5_1_0	C0235950	Zinc deficiency	6/50	90/21671	5.94499515318623e-08	1.74842307455207e-05	9.26167665970065e-06	RELA/MAPK3/MAPK14/STAT1/NFKB1/NPC1	6
group_G5_1_0	C0007787	Transient Ischemic Attack	9/50	344/21671	8.14416860296885e-08	2.09697780764292e-05	1.1108026826935e-05	OPTN/BECN1/SGK1/MFN2/PIK3CB/MAP1LC3A/NFKB1/HTRA2/IKBKB	9
group_G5_1_0	C1318485	Liver regeneration disorder	9/50	346/21671	8.55618282615267e-08	2.09697780764292e-05	1.1108026826935e-05	CEBPB/PRKAA1/PSEN1/MAPK3/MAPK14/STK11/STAT1/NFKB1/BCL2L1	9
group_G5_1_0	C0007113	Rectal Carcinoma	10/50	472/21671	1.02857257564333e-07	2.32694764997463e-05	1.23262138619605e-05	HRAS/TSC1/RAB5C/PIK3CB/MAPK3/MAPK14/STK11/NFKB1/BCL2L1/EPAS1	10
group_G5_1_0	C2826323	Refractory Cytopenia of Childhood	8/50	264/21671	1.50484650858219e-07	3.01574889596733e-05	1.59749042253142e-05	TFEB/TFE3/CEBPB/TSC1/PSEN1/MAPK3/MUL1/EPAS1	8
group_G5_1_0	C0279671	Cervical Squamous Cell Carcinoma	9/50	371/21671	1.54664156717158e-07	3.01574889596733e-05	1.59749042253142e-05	HRAS/BECN1/YY1/MFN2/PIK3CB/MAPK3/MAPK14/STAT1/NFKB1	9
group_G5_1_0	C0018800	Cardiomegaly	8/50	267/21671	1.64066583935659e-07	3.01574889596733e-05	1.59749042253142e-05	BECN1/YY1/MFN2/RELA/MAP1LC3A/MAPK3/SRC/STK11	8
group_G5_1_0	C0023470	Myeloid Leukemia	9/50	385/21671	2.11480360723975e-07	3.65861024052478e-05	1.93802435833736e-05	HRAS/BECN1/CEBPB/YY1/PIK3CB/MAPK3/MAPK14/STAT1/NFKB1	9
group_G5_1_0	C0206180	Ki-1+ Anaplastic Large Cell Lymphoma	8/50	300/21671	3.9824627146026e-07	6.50690157980346e-05	3.44680983486073e-05	CEBPB/YY1/PIK3CB/MAPK3/MAPK14/STAT1/NFKB1/BCL2L1	8
group_G5_1_0	C0339143	Thyroid associated opthalmopathies	7/50	211/21671	5.25856980382557e-07	8.13971252265842e-05	4.31173590562983e-05	CEBPB/PRKAA1/PIK3CB/MAPK3/STAT1/NFKB1/IKBKB	7
group_G5_1_0	C0020429	Hyperalgesia	9/50	451/21671	7.95054647519479e-07	0.000111505426837799	5.90662079564567e-05	BECN1/SGK1/MFN2/RELA/PIK3CB/MAP1LC3A/MAPK3/MAPK14/NFKB1	9
group_G5_1_0	C0238462	Medullary carcinoma of thyroid	8/50	330/21671	8.17401902278686e-07	0.000111505426837799	5.90662079564567e-05	HRAS/BECN1/PIK3CB/MAP1LC3A/MAPK3/SRC/STK11/NFKB1	8
group_G5_1_0	C0027055	Myocardial Reperfusion Injury	7/50	226/21671	8.34110639385098e-07	0.000111505426837799	5.90662079564567e-05	BECN1/MFN2/RELA/MAP1LC3A/MAPK3/STAT1/BCL2L1	7
group_G5_1_0	C0023492	Leukemia, T-Cell	9/50	457/21671	8.87208559506703e-07	0.00011344697276127	6.00946758842069e-05	YY1/RELA/PIK3CB/MAPK3/MAPK14/STAT1/NFKB1/IKBKB/BCL2L1	9
group_G5_1_0	C1519680	Tumor Immunity	8/50	337/21671	9.56896332811784e-07	0.000113918348778506	6.03443712994823e-05	CEBPB/PIK3CB/PIM2/RB1CC1/MAPK3/STK11/IKBKB/EPAS1	8
group_G5_1_0	C0235031	Neurologic Symptoms	7/50	233/21671	1.0230411999571e-06	0.000113918348778506	6.03443712994823e-05	TSC1/MFN2/PSEN1/PIK3CB/STAT1/NPC1/AP3B1	7
group_G5_1_0	C0158266	Intervertebral Disc Degeneration	8/50	342/21671	1.06856599480795e-06	0.000113918348778506	6.03443712994823e-05	TFEB/BECN1/RELA/RAB7A/PIK3CB/MAPK3/MAPK14/EPAS1	8
group_G5_1_0	C2347748	Adult Erythroleukemia	7/50	236/21671	1.11435015060171e-06	0.000113918348778506	6.03443712994823e-05	HRAS/BECN1/RELA/PIK3CB/MAPK3/STAT1/EPAS1	7
group_G5_1_0	C4520840	Erythroleukemia (Erythroid/Myeloid)	7/50	237/21671	1.14626537826175e-06	0.000113918348778506	6.03443712994823e-05	HRAS/BECN1/RELA/PIK3CB/MAPK3/STAT1/EPAS1	7
group_G5_1_0	C0278764	Adult Burkitt Lymphoma	9/50	475/21671	1.22141719787387e-06	0.000113918348778506	6.03443712994823e-05	TFE3/YY1/TSC1/PMAIP1/PIK3CB/MAPK3/MAPK14/NFKB1/NPC1	9
group_G5_1_0	C0334463	Malignant Fibrous Histiocytoma	6/50	150/21671	1.22959089489839e-06	0.000113918348778506	6.03443712994823e-05	HRAS/PIK3CB/MAPK14/SRC/STAT1/EPAS1	6
group_G5_1_0	C0278879	Childhood Burkitt Lymphoma	9/50	477/21671	1.26453118961954e-06	0.000113918348778506	6.03443712994823e-05	TFE3/YY1/TSC1/PMAIP1/PIK3CB/MAPK3/MAPK14/NFKB1/NPC1	9
group_G5_1_0	C1868683	B-CELL MALIGNANCY, LOW-GRADE	8/50	350/21671	1.27037237427027e-06	0.000113918348778506	6.03443712994823e-05	HRAS/RELA/PIK3CB/PIM2/MAPK14/STAT1/NFKB1/BCL2L1	8
group_G5_1_0	C0544886	Somatic mutation	6/50	151/21671	1.2782405677289e-06	0.000113918348778506	6.03443712994823e-05	TFE3/HRAS/TSC1/RB1CC1/SRC/STK11	6
group_G5_1_0	C4552000	Episodic Kinesigenic Dyskinesia 1	6/50	153/21671	1.38026808902277e-06	0.000117127260627582	6.20441832276245e-05	TSC1/PIK3CB/MAPK3/MAPK14/SRC/STK11	6
group_G5_1_0	C0949664	Tauopathies	7/50	245/21671	1.43031791563192e-06	0.000117127260627582	6.20441832276245e-05	TFEB/TSC1/RELA/PRKAA1/PSEN1/MAPK14/NPC1	7
group_G5_1_0	C0341858	Endometriosis of uterus	6/50	154/21671	1.43372369350321e-06	0.000117127260627582	6.20441832276245e-05	BECN1/CEBPB/RELA/PIK3CB/MAPK3/MUL1	6
group_G5_1_0	C0035112	Reoviridae Infections	4/50	38/21671	1.74649527379383e-06	0.000138822772979126	7.35366431071088e-05	RELA/ATG13/MAPK3/STAT1	4
group_G5_1_0	C2745900	Promyelocytic leukemia	7/50	255/21671	1.86623223196576e-06	0.000144436552479245	7.65103518922253e-05	CEBPB/RELA/PMAIP1/PIK3CB/PIM2/MAPK14/MUL1	7
group_G5_1_0	C0021655	Insulin Resistance	6/50	162/21671	1.92536919683629e-06	0.000145192584817834	7.69108343135685e-05	MFN2/RELA/PRKAA1/MAPK3/STK11/IKBKB	6
group_G5_1_0	C0242422	Parkinsonian Disorders	8/50	373/21671	2.041209885585e-06	0.000150079956837637	7.94997534385737e-05	BECN1/SGK1/RELA/PSEN1/SRC/HTRA2/NPC1/MUL1	8
group_G5_1_0	C4721773	Postoperative cognitive dysfunction	5/50	93/21671	2.37496485832439e-06	0.000170360284105659	9.02425671455736e-05	BAG3/BECN1/RELA/PRKAA1/PIK3CB	5
group_G5_1_0	C1512127	HER2 gene amplification	6/50	170/21671	2.54681066371482e-06	0.0001741900037671	9.22712309008064e-05	HRAS/BECN1/YY1/PIK3CB/MAPK3/MAPK14	6
group_G5_1_0	C1519689	Tumor Promotion	6/50	170/21671	2.54681066371482e-06	0.0001741900037671	9.22712309008064e-05	PIK3CB/MAPK3/STK11/STAT1/NPC1/IKBKB	6
group_G5_1_0	C1510885	Angiogenic Switch	5/50	96/21671	2.77876092915837e-06	0.000185059849964043	9.80291622780593e-05	CEBPB/PIK3CB/MAPK14/STK11/EPAS1	5
group_G5_1_0	C0032584	polyps	8/50	390/21671	2.8402162299835e-06	0.000185059849964043	9.80291622780593e-05	HRAS/RELA/PRKAA1/MAPK3/SRC/STK11/NFKB1/AP3B1	8
group_G5_1_0	C1290884	Inflammatory disorder	8/50	391/21671	2.89450972402107e-06	0.000185059849964043	9.80291622780593e-05	SGK1/PIK3CB/MAPK14/STK11/NFKB1/IKBKB/MUL1/EPAS1	8
group_G5_1_0	C0162557	Liver Failure, Acute	7/50	282/21671	3.63046962543833e-06	0.000227174705710939	0.000120338074930543	TFEB/BECN1/MFN2/RELA/PRKAA1/PIK3CB/STAT1	7
group_G5_1_0	C0175704	LEOPARD Syndrome	4/50	47/21671	4.1562012302757e-06	0.000254653912880017	0.000134894250456316	HRAS/TSC1/PIK3CB/MAPK3	4
group_G5_1_0	C0023267	Fibroid Tumor	8/50	413/21671	4.33350729567004e-06	0.000260098876664604	0.000137778534856964	HRAS/BECN1/CEBPB/TSC1/PIK3CB/SRC/STK11/IKBKB	8
group_G5_1_0	C0035288	Reticuloendotheliosis, X-linked	4/50	48/21671	4.52634793591056e-06	0.000263549087902832	0.000139606166930758	CEBPB/RELA/NFKB1/EPAS1	4
group_G5_1_0	C4551683	Adrenal Gland Pheochromocytoma	8/50	416/21671	4.57021539715895e-06	0.000263549087902832	0.000139606166930758	HRAS/PRKAA1/PIK3CB/MAPK3/MAPK14/RICTOR/SRC/EPAS1	8
group_G5_1_0	C0153633	Malignant neoplasm of brain	7/50	294/21671	4.77421128068313e-06	0.00027001837262479	0.000143033050514393	TFEB/HRAS/RELA/PIK3CB/MAPK3/STAT1/NPC1	7
group_G5_1_0	C0022665	Kidney Neoplasm	7/50	295/21671	4.88172935561314e-06	0.000270889925186005	0.000143494725845232	TFEB/TFE3/TSC1/PIK3CB/MAPK3/STK11/EPAS1	7
group_G5_1_0	C0812413	Malignant Pleural Mesothelioma	8/50	421/21671	4.98912674625491e-06	0.000271722625198809	0.000143935820359791	CEBPB/RELA/PRKAA1/PIK3CB/MAPK3/SRC/STAT1/MUL1	8
group_G5_1_0	C0023440	Acute Erythroblastic Leukemia	7/50	302/21671	5.69236703280259e-06	0.000304386389881317	0.000161238338919576	HRAS/BECN1/RELA/PIK3CB/MAPK3/STAT1/EPAS1	7
group_G5_1_0	C4049446	Neointimal hyperplasia	6/50	198/21671	6.13236262129375e-06	0.000321290123327865	0.000170192516875835	MFN2/PRKAA1/PIK3CB/MAPK3/MAPK14/NFKB1	6
group_G5_1_0	C0008928	Cleidocranial Dysplasia	4/50	52/21671	6.25503261767687e-06	0.000321290123327865	0.000170192516875835	CEBPB/PRKAA1/STK11/MUL1	4
group_G5_1_0	C0220724	CONSTRICTING BANDS, CONGENITAL	3/50	16/21671	6.33622140530982e-06	0.000321290123327865	0.000170192516875835	PSEN1/MAPK14/AP3B1	3
group_G5_1_0	C3811653	Experimental Organism Basal Cell Carcinoma	8/50	437/21671	6.55558777015914e-06	0.000326779383593865	0.000173100265831142	HRAS/PRKAA1/PIK3CB/MAPK3/MAPK14/STK11/STAT1/MUL1	8
group_G5_1_0	C0007766	Intracranial Aneurysm	7/50	311/21671	6.89660767368704e-06	0.000337533271384804	0.000178796772186156	TSC1/RELA/PIK3CB/STAT1/NFKB1/DRAM1/ATG14	7
group_G5_1_0	C1257763	Overnutrition	4/50	54/21671	7.28213985839264e-06	0.000337533271384804	0.000178796772186156	RELA/PRKAA1/NFKB1/IKBKB	4
group_G5_1_0	C1266050	Poorly Differentiated Thyroid Carcinoma	4/50	54/21671	7.28213985839264e-06	0.000337533271384804	0.000178796772186156	HRAS/RELA/PIK3CB/MAPK3	4
group_G5_1_0	C0338508	Optic Atrophy 1	5/50	117/21671	7.34516469521506e-06	0.000337533271384804	0.000178796772186156	OPTN/BECN1/MFN2/PRKAA1/MUL1	5
group_G5_1_0	C1337011	Well Differentiated Pancreatic Endocrine Tumor	5/50	117/21671	7.34516469521506e-06	0.000337533271384804	0.000178796772186156	TFE3/TSC1/PIK3CB/STK11/NFKB1	5
group_G5_1_0	C4518194	Epithelioid angiomyolipoma	3/50	17/21671	7.68147811341833e-06	0.000347557340485589	0.00018410668190865	TFE3/TSC1/PIK3CB	3
group_G5_1_0	C0429468	Anovulatory (finding)	4/50	55/21671	7.83997202227456e-06	0.00034935390481075	0.000185058350765014	ATG13/RB1CC1/MAPK3/ATG14	4
group_G5_1_0	C3714948	PACHYONYCHIA CONGENITA 3	6/50	209/21671	8.35507868478013e-06	0.000366750543461767	0.000194273628491353	BAG3/RELA/PRKAA1/PIK3CB/MAPK3/MAPK14	6
group_G5_1_0	C0017661	IGA Glomerulonephritis	8/50	456/21671	8.9393343395177e-06	0.000377675752171181	0.000200060886276901	OPTN/RELA/PIK3CB/MAPK3/MAPK14/STAT1/IKBKB/BCL2L1	8
group_G5_1_0	C2937358	Cerebral Hemorrhage	5/50	122/21671	9.00897051741079e-06	0.000377675752171181	0.000200060886276901	BECN1/RELA/MAP1LC3A/NFKB1/BCL2L1	5
group_G5_1_0	C0010606	Adenoid Cystic Carcinoma	7/50	325/21671	9.18692385017123e-06	0.000377675752171181	0.000200060886276901	TFE3/HRAS/BECN1/MFN2/PIK3CB/MAPK3/NFKB1	7
group_G5_1_0	C0553723	Squamous cell carcinoma of skin	8/50	458/21671	9.22821304008546e-06	0.000377675752171181	0.000200060886276901	TFEB/HRAS/BECN1/RELA/PIK3CB/MAPK3/SRC/STAT1	8
group_G5_1_0	C1368683	Epithelioma	7/50	326/21671	9.37215235994022e-06	0.000377675752171181	0.000200060886276901	TFE3/HRAS/SGK1/TSC1/PIK3CB/SRC/NPC1	7
group_G5_1_0	C0034494	Rabies (disorder)	5/50	123/21671	9.37447463736695e-06	0.000377675752171181	0.000200060886276901	RAB7A/PIK3CB/MAPK3/STAT1/MUL1	5
group_G5_1_0	C0349566	Squamous cell carcinoma of tongue	8/50	462/21671	9.82971824755056e-06	0.000390664883324948	0.000206941436790538	TFE3/BECN1/RELA/PIK3CB/MAPK3/SRC/NFKB1/EPAS1	8
group_G5_1_0	C0270921	Axonal neuropathy	4/50	59/21671	1.03913967655893e-05	0.000407481305167977	0.000215849364393996	BAG3/MFN2/RAB7A/MUL1	4
group_G5_1_0	C0279680	Transitional cell carcinoma of bladder	7/50	333/21671	1.07576560294007e-05	0.000416292978716677	0.000220517048802119	HRAS/TSC1/PIK3CB/MAPK3/MAPK14/SRC/NFKB1	7
group_G5_1_0	C1955869	Malformations of Cortical Development	4/50	60/21671	1.11147644077873e-05	0.000421956393769902	0.000223517050333562	HRAS/TSC1/PIK3CB/BCL2L1	4
group_G5_1_0	C0853897	Diabetic Cardiomyopathies	6/50	220/21671	1.1190955020079e-05	0.000421956393769902	0.000223517050333562	BECN1/SGK1/PRKAA1/PIK3CB/MAPK3/MAPK14	6
group_G5_1_0	C1332182	Adult Anaplastic Large Cell Lymphoma	5/50	128/21671	1.13796221495919e-05	0.000423638844834809	0.0002244082715709	CEBPB/YY1/MAPK3/MAPK14/STAT1	5
group_G5_1_0	C0276138	Viral myocarditis	5/50	129/21671	1.18180165643062e-05	0.000434459833945305	0.000230140322568067	RELA/MAPK3/MAPK14/STAT1/NFKB1	5
group_G5_1_0	C0085078	Lysosomal Storage Diseases	5/50	130/21671	1.22694945145695e-05	0.000440055894723766	0.000233104645462937	TFEB/PRKAA1/MCOLN1/NPC1/VPS11	5
group_G5_1_0	C1332942	Childhood Anaplastic Large Cell Lymphoma	5/50	130/21671	1.22694945145695e-05	0.000440055894723766	0.000233104645462937	CEBPB/YY1/MAPK3/MAPK14/STAT1	5
group_G5_1_0	C1292769	Precursor B-cell lymphoblastic leukemia	8/50	478/21671	1.25786293334512e-05	0.000445707817706989	0.000236098559461101	BECN1/YY1/RAB5C/PSEN1/PIK3CB/PIM2/SRC/MUL1	8
group_G5_1_0	C0442874	Neuropathy	8/50	484/21671	1.3764448703994e-05	0.000481919567124363	0.000255280502279589	BAG3/YY1/MFN2/RAB7A/PIK3CB/MAPK3/MAPK14/AMBRA1	8
group_G5_1_0	C0020443	Hypercholesterolemia	8/50	489/21671	1.48234270617287e-05	0.000512890576335812	0.000271686341193293	BECN1/RAB7A/PSEN1/PIK3CB/MAPK3/NPC1/IKBKB/ATG12	8
group_G5_1_0	C0206685	Acinar Cell Carcinoma	4/50	65/21671	1.53015581568084e-05	0.000523277703943878	0.000277188568813665	TFE3/HRAS/TSC1/STK11	4
group_G5_1_0	C4551472	Hypertrophic obstructive cardiomyopathy	6/50	233/21671	1.54990270905618e-05	0.00052393837555566	0.000277538537132868	HRAS/YY1/PRKAA1/PIK3CB/STK11/MUL1	6
group_G5_1_0	C0022336	Creutzfeldt-Jakob disease	5/50	137/21671	1.58197819450216e-05	0.000528704303412598	0.000280063125342488	OPTN/RAB7A/MAPK3/MAPK14/MUL1	5
group_G5_1_0	C0007873	Uterine Cervical Neoplasm	5/50	140/21671	1.75662349575013e-05	0.000580475247303497	0.00030748702231936	HRAS/YY1/MAPK3/STK11/EPAS1	5
group_G5_1_0	C2004493	Leukemia, B-Cell	6/50	239/21671	1.78948087398033e-05	0.000584762583375129	0.000309758092805953	BECN1/SGK1/YY1/PIK3CB/STK11/NFKB1	6
group_G5_1_0	C0017205	Gaucher Disease	5/50	143/21671	1.94594333795103e-05	0.000628903226034504	0.000333140097185371	TFEB/PSEN1/MAPK14/NPC1/MUL1	5
group_G5_1_0	C0011882	Diabetic Neuropathies	5/50	144/21671	2.01245769298746e-05	0.000643330225551751	0.00034078230956767	BECN1/SGK1/RELA/MAPK3/MAPK14	5
group_G5_1_0	C4703473	Atherosclerotic lesion	6/50	253/21671	2.46601304836916e-05	0.000765535023037148	0.000405516145276393	RELA/ATG13/PIK3CB/STAT1/NFKB1/IKBKB	6
group_G5_1_0	C0029454	Osteopetrosis	4/50	74/21671	2.56109575595882e-05	0.000765535023037148	0.000405516145276393	TSC1/MCOLN1/SRC/NFKB1	4
group_G5_1_0	C0410480	Avascular Necrosis of Femur Head	4/50	74/21671	2.56109575595882e-05	0.000765535023037148	0.000405516145276393	BECN1/RELA/PIK3CB/STAT1	4
group_G5_1_0	C0272139	Erythrocytosis due to low atmospheric pressure	3/50	25/21671	2.56456735643489e-05	0.000765535023037148	0.000405516145276393	YY1/PIK3CB/EPAS1	3
group_G5_1_0	C2828150	HPV positive oropharyngeal squamous cell carcinoma	3/50	25/21671	2.56456735643489e-05	0.000765535023037148	0.000405516145276393	HRAS/PIK3CB/STAT1	3
group_G5_1_0	C4745063	Biliary Tract Carcinoma	3/50	25/21671	2.56456735643489e-05	0.000765535023037148	0.000405516145276393	HRAS/PIK3CB/SRC	3
group_G5_1_0	C0752347	Lewy Body Disease	6/50	255/21671	2.5775325474536e-05	0.000765535023037148	0.000405516145276393	TFEB/BECN1/PSEN1/HTRA2/MUL1/BCL2L1	6
group_G5_1_0	C3875321	Inflammatory dermatosis	7/50	382/21671	2.60297525684171e-05	0.000765535023037148	0.000405516145276393	RELA/PIK3CB/MAPK3/MAPK14/STAT1/IKBKB/EPAS1	7
group_G5_1_0	C0342649	Vascular calcification	6/50	257/21671	2.69308112420876e-05	0.000784193226366135	0.00041539969398947	BECN1/SGK1/PRKAA1/MAPK14/IKBKB/MUL1	6
group_G5_1_0	C2931852	Clear-cell metastatic renal cell carcinoma	6/50	260/21671	2.87419583980538e-05	0.000828726467143884	0.000438989663871203	TFE3/PIK3CB/MAPK3/STK11/MUL1/EPAS1	6
group_G5_1_0	C0751690	Malignant Peripheral Nerve Sheath Tumor	6/50	261/21671	2.93670041260306e-05	0.000838527758588893	0.000444181564706441	HRAS/BECN1/TSC1/PIK3CB/MAPK3/STAT1	6
group_G5_1_0	C0282160	Aplasia Cutis Congenita	7/50	393/21671	3.11968561923747e-05	0.000882211096747827	0.000467321327578082	BECN1/TSC1/PRKAA1/PMAIP1/PIK3CB/SRC/STK11	7
group_G5_1_0	C0279543	Philadelphia chromosome positive chronic myelogenous leukemia	3/50	27/21671	3.25087489681311e-05	0.000910554578240702	0.000482335323035931	HRAS/YY1/SRC	3
group_G5_1_0	C0376618	Endotoxemia	7/50	401/21671	3.5463059702894e-05	0.000980801090171512	0.000519546023892281	PRKAA1/PIK3CB/MAPK3/MAPK14/STK11/STAT1/SIRT5	7
group_G5_1_0	C0023804	Lipomatosis, Multiple Symmetrical	3/50	28/21671	3.63506694419227e-05	0.000980801090171512	0.000519546023892281	MFN2/PIK3CB/MAPK3	3
group_G5_1_0	C0265316	Neurocutaneous Syndromes	3/50	28/21671	3.63506694419227e-05	0.000980801090171512	0.000519546023892281	HRAS/TSC1/PIK3CB	3
group_G5_1_0	C4522181	Brachial Amyotrophic Diplegia	3/50	28/21671	3.63506694419227e-05	0.000980801090171512	0.000519546023892281	HRAS/PIK3CB/MAPK3	3
group_G5_1_0	C4284013	Primary cholangiocarcinoma of intrahepatic biliary tract	6/50	274/21671	3.85371153809717e-05	0.00102482534846095	0.000542866377609552	HRAS/BECN1/PIK3CB/MAPK3/SRC/STK11	6
group_G5_1_0	C0027746	Nerve Degeneration	5/50	165/21671	3.86792294046806e-05	0.00102482534846095	0.000542866377609552	OPTN/BECN1/PSEN1/MAP1LC3A/MAPK3	5
group_G5_1_0	C2936719	Mechanical Allodynia	7/50	408/21671	3.95797956668481e-05	0.0010393230272875	0.000550546029952398	CEBPB/MFN2/RELA/PRKAA1/PIK3CB/MAPK3/MAPK14	7
group_G5_1_0	C0035869	Rotavirus Infections	4/50	84/21671	4.22253026702057e-05	0.00109340765493192	0.000579195522217377	PIK3CB/MAPK3/MAPK14/STAT1	4
group_G5_1_0	C0016057	Fibrosarcoma	7/50	413/21671	4.27548045961138e-05	0.00109340765493192	0.000579195522217377	HRAS/RELA/PIK3CB/MAPK14/STAT1/NFKB1/BCL2L1	7
group_G5_1_0	C2973725	Pulmonary arterial hypertension	7/50	413/21671	4.27548045961138e-05	0.00109340765493192	0.000579195522217377	MFN2/PRKAA1/PIK3CB/MAPK3/SRC/STAT1/EPAS1	7
group_G5_1_0	C0038436	Post-Traumatic Stress Disorder	7/50	418/21671	4.61364271111247e-05	0.00115972902887901	0.000614327014707112	BAG3/BECN1/SGK1/YY1/PMAIP1/MAPK3/NFKB1	7
group_G5_1_0	C0205698	Undifferentiated carcinoma	6/50	283/21671	4.61367889761456e-05	0.00115972902887901	0.000614327014707112	HRAS/SGK1/MAP1LC3A/MAPK3/NPC1/BCL2L1	6
group_G5_1_0	C1300127	Perivascular Epithelioid Cell Neoplasms	3/50	31/21671	4.96341887734855e-05	0.00122916318272465	0.000651107396493312	TFEB/TFE3/TSC1	3
group_G5_1_0	C0685938	Malignant neoplasm of gastrointestinal tract	7/50	423/21671	4.97349264686276e-05	0.00122916318272465	0.000651107396493312	BAG3/HRAS/PIK3CB/MAPK3/RICTOR/STK11/MUL1	7
group_G5_1_0	C1960398	HER2-positive carcinoma of breast	6/50	288/21671	5.08514554384203e-05	0.0012444591963777	0.000659209939561908	PRKAA1/PIK3CB/MAPK3/STK11/STAT1/EPAS1	6
group_G5_1_0	C0162534	Prion Diseases	5/50	175/21671	5.12001233463793e-05	0.0012444591963777	0.000659209939561908	PRKAA1/PSEN1/PIK3CB/NFKB1/MUL1	5
group_G5_1_0	C0542476	Forgetful	7/50	429/21671	5.43543611788718e-05	0.00129688237703032	0.000686979336783006	BECN1/PRKAA1/PSEN1/PIK3CB/MAPK3/MAPK14/STAT1	7
group_G5_1_0	C0032027	Pityriasis Rubra Pilaris	3/50	32/21671	5.46798418061069e-05	0.00129688237703032	0.000686979336783006	RELA/PIK3CB/MAPK3	3
group_G5_1_0	C4316899	Cystinosis	3/50	32/21671	5.46798418061069e-05	0.00129688237703032	0.000686979336783006	TFEB/PRKAA1/RAB7A	3
group_G5_1_0	C0008497	Choriocarcinoma	7/50	431/21671	5.59702326119489e-05	0.00131686763289393	0.000697565846447868	RELA/PIK3CB/PIM2/MAPK3/STK11/STAT1/EPAS1	7
group_G5_1_0	C0206716	Ganglioglioma	4/50	91/21671	5.77989498715833e-05	0.00134910088549466	0.000714640315872542	BECN1/TSC1/PIK3CB/STK11	4
group_G5_1_0	C4518356	MiT family translocation renal cell carcinoma	3/50	33/21671	6.00501819157418e-05	0.0013906109056236	0.000736628837424765	TFEB/TFE3/PIK3CB	3
group_G5_1_0	C0034885	Rectal Neoplasms	4/50	93/21671	6.29282931284026e-05	0.00144587586008306	0.000765903567681216	HRAS/TSC1/PRKAA1/STK11	4
group_G5_1_0	C0035126	Reperfusion Injury	6/50	300/21671	6.37540770977049e-05	0.00145349411429729	0.000769939078780932	BAG3/BECN1/RELA/MAPK14/SRC/STAT1	6
group_G5_1_0	C0015696	Fatty Liver, Alcoholic	4/50	94/21671	6.56138149341745e-05	0.00148438638247236	0.000786303207308326	MFN2/RELA/STK11/NFKB1	4
group_G5_1_0	C0027659	Neoplasms, Experimental	4/50	95/21671	6.83819564177584e-05	0.00152828449920717	0.000809556741826665	HRAS/RELA/MAPK3/EPAS1	4
group_G5_1_0	C0595921	Intraocular pressure disorder	6/50	304/21671	6.85935239358539e-05	0.00152828449920717	0.000809556741826665	OPTN/CEBPB/PIK3CB/MAPK3/MAPK14/SRC	6
group_G5_1_0	C0206624	Hepatoblastoma	7/50	452/21671	7.54484689636464e-05	0.00166837554302319	0.000883765208280148	BECN1/CEBPB/YY1/PIK3CB/PIM2/MAPK3/DRAM1	7
group_G5_1_0	C3887640	Astrocytosis	3/50	37/21671	8.4964807023743e-05	0.00186478729445394	0.0009878076543216	TSC1/PSEN1/MAPK3	3
group_G5_1_0	C0010823	Cytomegalovirus Infections	7/50	462/21671	8.65028853041816e-05	0.00188448137540443	0.000998239923978081	HRAS/RELA/MAPK3/MAPK14/STAT1/NFKB1/IKBKB	7
group_G5_1_0	C0026847	Spinal Muscular Atrophy	6/50	320/21671	9.09732317913168e-05	0.00195951820672947	0.00103798813363146	BECN1/RELA/MAPK14/NFKB1/HTRA2/BCL2L1	6
group_G5_1_0	C4721414	Mantle cell lymphoma	7/50	466/21671	9.12798348595503e-05	0.00195951820672947	0.00103798813363146	PMAIP1/PIK3CB/PIM2/MAPK3/STAT1/NFKB1/MUL1	7
group_G5_1_0	C0345905	Intrahepatic Cholangiocarcinoma	7/50	470/21671	9.62702459687426e-05	0.00203749893941217	0.00107929577491723	HRAS/BECN1/PIK3CB/MAPK3/MAPK14/SRC/STK11	7
group_G5_1_0	C0023827	liposarcoma	5/50	200/21671	9.62979777552843e-05	0.00203749893941217	0.00107929577491723	CEBPB/PIK3CB/MAPK14/SRC/EPAS1	5
group_G5_1_0	C0431391	Hemimegalencephaly	3/50	39/21671	9.96107228438883e-05	0.00209253668488482	0.00110845014893951	HRAS/TSC1/PIK3CB	3
group_G5_1_0	C1969372	Tubulointerstitial fibrosis	6/50	328/21671	0.00010416051077496	0.00217259618573871	0.00115085894697231	CEBPB/SGK1/PIK3CB/MAPK3/MAPK14/STAT1	6
group_G5_1_0	C0150080	Social Communication Disorder	3/50	40/21671	0.000107512538458015	0.00222672095496494	0.00117952970287518	TSC1/PIK3CB/HTRA2	3
group_G5_1_0	C0033141	Cardiomyopathies, Primary	4/50	108/21671	0.000112604736278385	0.00229979534301895	0.00121823837494159	HRAS/PSEN1/MAPK3/MAPK14	4
group_G5_1_0	C0242363	Islet Cell Tumor	4/50	108/21671	0.000112604736278385	0.00229979534301895	0.00121823837494159	TFE3/TSC1/STK11/NFKB1	4
group_G5_1_0	C0007965	Chediak-Higashi Syndrome	3/50	41/21671	0.000115812166341745	0.00234899021524876	0.00124429768555922	PRKAA1/RAB7A/AP3B1	3
group_G5_1_0	C0079772	T-Cell Lymphoma	7/50	485/21671	0.000117010491567917	0.00235704010754277	0.00124856184225319	BAG3/HRAS/BECN1/YY1/PIK3CB/NFKB1/IKBKB	7
group_G5_1_0	C0036220	Kaposi Sarcoma	7/50	488/21671	0.000121565925339739	0.00243214548587873	0.00128834636235456	CEBPB/TSC1/PIK3CB/NFKB1/MUL1/BCL2L1/EPAS1	7
group_G5_1_0	C1333015	Childhood Kidney Wilms Tumor	6/50	338/21671	0.000122739569789822	0.00243854746671566	0.00129173759399387	HRAS/BECN1/PIK3CB/MAPK3/STK11/STAT1	6
group_G5_1_0	C0238065	Secondary Biliary Cholangitis	3/50	42/21671	0.000124518457003096	0.00243854746671566	0.00129173759399387	RELA/MAPK14/NFKB1	3
group_G5_1_0	C4551595	Biliary Cirrhosis, Primary, 1	3/50	42/21671	0.000124518457003096	0.00243854746671566	0.00129173759399387	RELA/MAPK14/NFKB1	3
group_G5_1_0	C1853237	Isolated cases	4/50	111/21671	0.000125202539093528	0.00243854746671566	0.00129173759399387	HRAS/TSC1/PSEN1/STK11	4
group_G5_1_0	C0011603	Dermatitis	7/50	496/21671	0.000134424655215059	0.0025967889500523	0.00137556063855022	RELA/PIK3CB/MAPK3/MAPK14/STAT1/IKBKB/EPAS1	7
group_G5_1_0	C0031511	Pheochromocytoma	6/50	344/21671	0.000135093066765726	0.0025967889500523	0.00137556063855022	HRAS/PIK3CB/MAPK3/MAPK14/SRC/EPAS1	6
group_G5_1_0	C2349952	Oropharyngeal Carcinoma	4/50	115/21671	0.000143550408356451	0.00274143994140468	0.00145218458214318	PMAIP1/PIK3CB/NFKB1/NPC1	4
group_G5_1_0	C1175175	Severe Acute Respiratory Syndrome	4/50	117/21671	0.000153419656800642	0.0029110142622625	0.00154201081198608	BAG3/MAPK14/MUL1/BCL2L1	4
group_G5_1_0	C1851710	LATERAL MENINGOCELE SYNDROME	4/50	118/21671	0.000158534139033277	0.00298877501856967	0.00158320192826755	HRAS/PIK3CB/SRC/STAT1	4
group_G5_1_0	C4733092	estrogen receptor-negative breast cancer	6/50	356/21671	0.000162758634014351	0.00304495950291561	0.00161296374821135	TSC1/PIK3CB/MAPK3/MAPK14/STAT1/EPAS1	6
group_G5_1_0	C0431718	Multiple renal cysts	3/50	46/21671	0.000163585039599002	0.00304495950291561	0.00161296374821135	TSC1/STK11/EPAS1	3
group_G5_1_0	C0041327	Tuberculosis, Pulmonary	6/50	358/21671	0.000167776686096576	0.00308953896733475	0.0016365782034952	BECN1/YY1/TSC1/RELA/MAPK14/NFKB1	6
group_G5_1_0	C0917798	Cerebral Ischemia	4/50	120/21671	0.000169131510962562	0.00308953896733475	0.0016365782034952	CEBPB/RELA/MAPK3/NFKB1	4
group_G5_1_0	C1863753	LIMB-MAMMARY SYNDROME	4/50	120/21671	0.000169131510962562	0.00308953896733475	0.0016365782034952	HRAS/PIK3CB/SRC/STAT1	4
group_G5_1_0	C0041956	Ureteral obstruction	6/50	359/21671	0.000170331281638869	0.00309224876111058	0.00163801362459731	SGK1/RELA/PRKAA1/PIK3CB/MAPK14/NFKB1	6
group_G5_1_0	C0158570	Vascular anomaly	3/50	47/21671	0.000174455187669598	0.00314768531862753	0.00166737925573784	TSC1/PIK3CB/EPAS1	3
group_G5_1_0	C0282488	Interstitial Cystitis	4/50	122/21671	0.000180231759233392	0.00320426682456205	0.00169735138436688	OPTN/MFN2/PIK3CB/MAP1LC3A	4
group_G5_1_0	C1318544	M5b Acute differentiated monocytic leukemia	4/50	122/21671	0.000180231759233392	0.00320426682456205	0.00169735138436688	RELA/PRKAA1/PIK3CB/BCL2L1	4
group_G5_1_0	C0037286	Skin Neoplasms	6/50	363/21671	0.000180859671158552	0.00320426682456205	0.00169735138436688	HRAS/TSC1/RELA/PSEN1/MAPK14/IKBKB	6
group_G5_1_0	C2674218	SPHEROCYTOSIS, TYPE 1 (disorder)	3/50	48/21671	0.000185783776985177	0.00327179693481081	0.00173312316380751	PRKAA1/PMAIP1/MAPK3	3
group_G5_1_0	C0018671	Head and Neck Neoplasms	4/50	124/21671	0.000191848974089564	0.00333946240659324	0.00176896664641744	PIK3CB/MAPK3/BCL2L1/EPAS1	4
group_G5_1_0	C0079773	Lymphoma, T-Cell, Cutaneous	6/50	367/21671	0.00019189702370427	0.00333946240659324	0.00176896664641744	PIK3CB/MAPK3/STAT1/NFKB1/IKBKB/MUL1	6
group_G5_1_0	C0026691	Mucocutaneous Lymph Node Syndrome	6/50	370/21671	0.000200519586181682	0.00346898884094309	0.00183757887027176	BECN1/RELA/MAPK3/MAPK14/SRC/STAT1	6
group_G5_1_0	C1839259	Bulbo-Spinal Atrophy, X-Linked	4/50	126/21671	0.000203997346146407	0.0035085157603309	0.00185851691164471	BAG3/TFEB/BECN1/STAT1	4
group_G5_1_0	C0014378	Enterovirus Infections	5/50	237/21671	0.000212757688818298	0.00363790908613148	0.00192705862577161	BECN1/PIK3CB/MAPK3/MAPK14/STAT1	5
group_G5_1_0	C1262048	Glial scar	3/50	51/21671	0.00022260400022018	0.00377338926291388	0.00199882464221355	RELA/RAB7A/PIK3CB	3
group_G5_1_0	C1851841	ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1	4/50	129/21671	0.000223247103620202	0.00377338926291388	0.00199882464221355	PIK3CB/MAPK14/STK11/VPS11	4
group_G5_1_0	C0023524	Leukoencephalopathy, Progressive Multifocal	5/50	240/21671	0.000225518155428412	0.00378999368637119	0.0020076202708815	CEBPB/RELA/MAPK14/STAT1/MUL1	5
group_G5_1_0	C0282193	Iron Overload	5/50	241/21671	0.000229898693723428	0.00384165942182161	0.0020349884372648	PIK3CB/MCOLN1/MAPK14/BCL2L1/EPAS1	5
group_G5_1_0	C0920646	Ischemia of kidney	4/50	131/21671	0.000236786080252322	0.00393439470068972	0.00208411179764161	PIK3CB/MAPK14/STAT1/EPAS1	4
group_G5_1_0	C0027533	Neck Neoplasms	4/50	132/21671	0.000243772744999455	0.00402371603994253	0.00213142673960341	HRAS/MAPK3/NFKB1/BCL2L1	4
group_G5_1_0	C0149678	Epstein-Barr Virus Infections	6/50	384/21671	0.000244898052074027	0.00402371603994253	0.00213142673960341	CEBPB/RELA/PIK3CB/MAPK14/NFKB1/NPC1	6
group_G5_1_0	C0278595	Adult Fibrosarcoma	6/50	387/21671	0.000255344131406352	0.00417203939147823	0.0022099959911193	HRAS/RELA/PIK3CB/MAPK14/STAT1/NFKB1	6
group_G5_1_0	C0042164	Uveitis	5/50	247/21671	0.000257560485326057	0.00417217272222535	0.00221006661854848	RELA/PIK3CB/MAPK3/MAPK14/STAT1	5
group_G5_1_0	C1266043	Sarcomatoid Renal Cell Carcinoma	4/50	134/21671	0.00025818953942367	0.00417217272222535	0.00221006661854848	TFE3/TSC1/RELA/EPAS1	4
group_G5_1_0	C0862506	Borderline ovarian tumour	3/50	54/21671	0.000263849328935727	0.00424033265792335	0.00224617202660268	HRAS/BECN1/PIK3CB	3
group_G5_1_0	C0008373	Cholesteatoma	4/50	135/21671	0.000265623329525996	0.00424564245726062	0.00224898471223383	BECN1/PIK3CB/MAPK3/MAPK14	4
group_G5_1_0	C1300257	Thanatophoric dysplasia, type 2	2/50	11/21671	0.000283150914914635	0.00447713355249431	0.00237160924772869	MAPK3/STAT1	2
group_G5_1_0	C1860991	NOONAN SYNDROME 3	2/50	11/21671	0.000283150914914635	0.00447713355249431	0.00237160924772869	HRAS/MAPK3	2
group_G5_1_0	C1266119	Solitary fibrous tumor	3/50	58/21671	0.00032610419988789	0.00506628018004107	0.00268368963884851	RELA/MAPK3/MAPK14	3
group_G5_1_0	C2931367	Thyroid cancer, follicular	3/50	58/21671	0.00032610419988789	0.00506628018004107	0.00268368963884851	HRAS/PIK3CB/STK11	3
group_G5_1_0	C0039483	Giant Cell Arteritis	5/50	260/21671	0.000326138715769411	0.00506628018004107	0.00268368963884851	PIK3CB/STAT1/NFKB1/IKBKB/MUL1	5
group_G5_1_0	C0007621	Neoplastic Cell Transformation	4/50	143/21671	0.000330746614949978	0.00506628018004107	0.00268368963884851	HRAS/RELA/NFKB1/EPAS1	4
group_G5_1_0	C0278608	Adult Liposarcoma	4/50	143/21671	0.000330746614949978	0.00506628018004107	0.00268368963884851	CEBPB/PIK3CB/SRC/EPAS1	4
group_G5_1_0	C0279984	Childhood Liposarcoma	4/50	143/21671	0.000330746614949978	0.00506628018004107	0.00268368963884851	CEBPB/PIK3CB/SRC/EPAS1	4
group_G5_1_0	C0039743	Thanatophoric Dysplasia	2/50	12/21671	0.000339280001551456	0.00517006468685406	0.0027386659519834	HRAS/STAT1	2
group_G5_1_0	C0023485	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	4/50	145/21671	0.000348665905807974	0.0052857032421714	0.0027999215441986	BECN1/PIK3CB/SRC/MUL1	4
group_G5_1_0	C0086942	Rous Sarcoma	3/50	60/21671	0.000360485944788477	0.00543686750575851	0.00287999567226421	HRAS/PIK3CB/SRC	3
group_G5_1_0	C0748355	Acute respiratory distress	4/50	147/21671	0.000367270571196048	0.00551093239738559	0.00291922902991488	RELA/PIK3CB/NFKB1/EPAS1	4
group_G5_1_0	C0013363	Dysautonomia	4/50	148/21671	0.00037683463790551	0.00562573944203099	0.0029800441576284	PIK3CB/MAPK3/HTRA2/VPS11	4
group_G5_1_0	C0018553	Hamartoma Syndrome, Multiple	5/50	270/21671	0.000387688343002837	0.00572960510940374	0.00303506346280983	TSC1/RELA/PIK3CB/MAPK14/STK11	5
group_G5_1_0	C0940937	precancerous lesions	5/50	270/21671	0.000387688343002837	0.00572960510940374	0.00303506346280983	BAG3/PIK3CB/MAPK14/MUL1/BCL2L1	5
group_G5_1_0	C0221500	Effects of heat	2/50	13/21671	0.000400376032576561	0.00585823836720232	0.00310320255675994	PIK3CB/MAPK3	2
group_G5_1_0	C1306571	Hepatic Insufficiency	2/50	13/21671	0.000400376032576561	0.00585823836720232	0.00310320255675994	RELA/MAPK14	2
group_G5_1_0	C1608389	Autoimmune myocarditis	3/50	63/21671	0.000416300468794381	0.00603962652403713	0.00319928676446427	CEBPB/PIK3CB/MAPK14	3
group_G5_1_0	C0340643	Dissection of aorta	4/50	152/21671	0.000416880035491172	0.00603962652403713	0.00319928676446427	MFN2/RAB7A/MAPK3/STAT1	4
group_G5_1_0	C0206694	Mucoepidermoid Carcinoma	4/50	153/21671	0.000427348182745989	0.00611917456267139	0.00324142463277928	BECN1/PIK3CB/MAPK3/IKBKB	4
group_G5_1_0	C0021125	Impulsive Behavior	5/50	276/21671	0.000428612703131692	0.00611917456267139	0.00324142463277928	BAG3/RELA/MAPK3/AMBRA1/HTRA2	5
group_G5_1_0	C0022680	Polycystic Kidney Diseases	5/50	276/21671	0.000428612703131692	0.00611917456267139	0.00324142463277928	BECN1/TSC1/PIK3CB/STK11/EPAS1	5
group_G5_1_0	C0343641	Human papilloma virus infection	6/50	429/21671	0.000442058485784955	0.00628064737533118	0.00332695936415832	HRAS/BECN1/RELA/PIK3CB/STK11/NFKB1	6
group_G5_1_0	C0085413	Polycystic Kidney, Autosomal Dominant	5/50	280/21671	0.000457655529956135	0.0064099604915844	0.00339545859000516	TSC1/MFN2/PRKAA1/PIK3CB/STAT1	5
group_G5_1_0	C0206686	Adrenocortical carcinoma	5/50	281/21671	0.000465142909927543	0.0064099604915844	0.00339545859000516	TFE3/HRAS/SGK1/MAPK14/STK11	5
group_G5_1_0	C0278804	Adenocarcinoma of duodenum	2/50	14/21671	0.000466416710370303	0.0064099604915844	0.00339545859000516	BECN1/RICTOR	2
group_G5_1_0	C0400807	Stress ulcer of stomach	2/50	14/21671	0.000466416710370303	0.0064099604915844	0.00339545859000516	RELA/MAPK14	2
group_G5_1_0	C1846385	FOCAL CORTICAL DYSPLASIA OF TAYLOR	2/50	14/21671	0.000466416710370303	0.0064099604915844	0.00339545859000516	TSC1/PIK3CB	2
group_G5_1_0	C1848980	Developmental stagnation	2/50	14/21671	0.000466416710370303	0.0064099604915844	0.00339545859000516	MCOLN1/VPS11	2
group_G5_1_0	C2741638	Stress ulcer	2/50	14/21671	0.000466416710370303	0.0064099604915844	0.00339545859000516	RELA/MAPK14	2
group_G5_1_0	C0035222	Respiratory Distress Syndrome, Adult	6/50	434/21671	0.000469966527627313	0.00641093280960898	0.00339597364241353	RELA/PIK3CB/MAPK14/NFKB1/IKBKB/EPAS1	6
group_G5_1_0	C4722419	Extrapulmonary Small Cell Carcinoma	4/50	157/21671	0.000471105305985366	0.00641093280960898	0.00339597364241353	PIK3CB/MAP1LC3A/RICTOR/STAT1	4
group_G5_1_0	C0001339	Acute pancreatitis	6/50	435/21671	0.000475709830393885	0.00641093280960898	0.00339597364241353	TFEB/BECN1/RELA/RAB7A/PIK3CB/MAPK14	6
group_G5_1_0	C0005944	Metabolic Bone Disorder	3/50	66/21671	0.000477386700205497	0.00641093280960898	0.00339597364241353	BECN1/PRKAA1/PIK3CB	3
group_G5_1_0	C0221271	Elastosis perforans serpiginosa	3/50	66/21671	0.000477386700205497	0.00641093280960898	0.00339597364241353	RELA/PSEN1/MAPK3	3
group_G5_1_0	C0027668	Neoplasms, Vascular Tissue	3/50	67/21671	0.000498954938206081	0.00667012033301857	0.0035332694188756	TFE3/TSC1/RICTOR	3
group_G5_1_0	C0162770	Right Ventricular Hypertrophy	4/50	160/21671	0.000505955691732146	0.00673310266689703	0.00356663216843809	PRKAA1/PIK3CB/MAPK14/EPAS1	4
group_G5_1_0	C0007758	Cerebellar Ataxia	6/50	441/21671	0.000511332101705808	0.00677399869872424	0.00358829545056707	PSEN1/PIK3CB/MAPK14/NPC1/IKBKB/MUL1	6
group_G5_1_0	C0474808	Follicular neoplasm	3/50	68/21671	0.00052113844834008	0.00687295146443128	0.00364071231316176	HRAS/RELA/BCL2L1	3
group_G5_1_0	C1266044	Collecting Duct Carcinoma of the Kidney	4/50	162/21671	0.000530186079927777	0.00693172816583094	0.00367184727193751	TFE3/TSC1/RELA/EPAS1	4
group_G5_1_0	C0020192	Hyaline Membrane Disease	2/50	15/21671	0.000537379810203827	0.00693172816583094	0.00367184727193751	NFKB1/EPAS1	2
group_G5_1_0	C0154017	Benign neoplasm of bladder	2/50	15/21671	0.000537379810203827	0.00693172816583094	0.00367184727193751	HRAS/TSC1	2
group_G5_1_0	C0496930	Neoplasm of uncertain or unknown behavior of bladder	2/50	15/21671	0.000537379810203827	0.00693172816583094	0.00367184727193751	HRAS/TSC1	2
group_G5_1_0	C2363866	Traumatic occlusion	2/50	15/21671	0.000537379810203827	0.00693172816583094	0.00367184727193751	MAPK3/MAPK14	2
group_G5_1_0	C0032463	Polycythemia Vera	5/50	291/21671	0.000545207406411156	0.0069715434011096	0.00369293803884902	PIK3CB/MAPK3/STAT1/NFKB1/BCL2L1	5
group_G5_1_0	C0040100	Thymoma	5/50	291/21671	0.000545207406411156	0.0069715434011096	0.00369293803884902	HRAS/PIK3CB/MAPK3/MAPK14/STAT1	5
group_G5_1_0	C0282687	Hemorrhagic Fever, Ebola	4/50	164/21671	0.000555231969457415	0.00706899230378467	0.00374455828114365	BAG3/STAT1/NPC1/MUL1	4
group_G5_1_0	C0206682	Follicular thyroid carcinoma	5/50	293/21671	0.000562391878674416	0.00712928670336835	0.00377649718892076	HRAS/YY1/PIK3CB/MAPK3/STK11	5
group_G5_1_0	C0279646	Childhood Acute Monocytic Leukemia	3/50	70/21671	0.000567380148499342	0.00713104708007079	0.0037774296886146	RELA/PRKAA1/PIK3CB	3
group_G5_1_0	C0280634	Adult Acute Monocytic Leukemia	3/50	70/21671	0.000567380148499342	0.00713104708007079	0.0037774296886146	RELA/PRKAA1/PIK3CB	3
group_G5_1_0	C0162309	Adrenoleukodystrophy	5/50	294/21671	0.000571135494385939	0.00714769995314488	0.00378625098181944	BECN1/PRKAA1/PIK3CB/MAPK3/MAPK14	5
group_G5_1_0	C0013421	Dystonia	6/50	453/21671	0.000588809136196207	0.00724775909912183	0.00383925391173797	YY1/PSEN1/MCOLN1/HTRA2/NPC1/VPS11	6
group_G5_1_0	C0334634	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	5/50	296/21671	0.000588929320573633	0.00724775909912183	0.00383925391173797	PMAIP1/PIK3CB/PIM2/STAT1/MUL1	5
group_G5_1_0	C0031269	Peutz-Jeghers Syndrome	3/50	71/21671	0.00059145262964612	0.00724775909912183	0.00383925391173797	TSC1/PRKAA1/STK11	3
group_G5_1_0	C0276275	Disease due to Parvoviridae	3/50	71/21671	0.00059145262964612	0.00724775909912183	0.00383925391173797	RELA/MAPK14/STAT1	3
group_G5_1_0	C0677659	Gastro-esophageal reflux disease with esophagitis	3/50	71/21671	0.00059145262964612	0.00724775909912183	0.00383925391173797	PIK3CB/MAPK14/EPAS1	3
group_G5_1_0	C0010414	Infection by Cryptococcus neoformans	4/50	167/21671	0.000594363843652229	0.00725321188456932	0.00384214233939856	GORASP2/PRKAA1/STAT1/NFKB1	4
group_G5_1_0	C0005122	Beriberi	2/50	16/21671	0.000613243180032186	0.00730181454443181	0.00386788794565367	BECN1/PSEN1	2
group_G5_1_0	C0006009	Borderline intellectual disability	2/50	16/21671	0.000613243180032186	0.00730181454443181	0.00386788794565367	BAG3/VPS11	2
group_G5_1_0	C0023801	Lipomatosis	2/50	16/21671	0.000613243180032186	0.00730181454443181	0.00386788794565367	MFN2/PIK3CB	2
group_G5_1_0	C0154091	Carcinoma in situ of bladder	2/50	16/21671	0.000613243180032186	0.00730181454443181	0.00386788794565367	HRAS/TSC1	2
group_G5_1_0	C0410606	Cervical Disc Degenerative Disorder	2/50	16/21671	0.000613243180032186	0.00730181454443181	0.00386788794565367	BECN1/MAP1LC3A	2
group_G5_1_0	C4551508	Dominant hereditary optic atrophy	2/50	16/21671	0.000613243180032186	0.00730181454443181	0.00386788794565367	OPTN/MFN2	2
group_G5_1_0	C0039101	synovial sarcoma	5/50	299/21671	0.000616398117683369	0.00730978574236608	0.0038721104166867	PIK3CB/MAPK3/MAPK14/SRC/NFKB1	5
group_G5_1_0	C0086565	Liver Dysfunction	3/50	73/21671	0.000641536162657742	0.00754703141750567	0.00399778324519351	NFKB1/NPC1/BCL2L1	3
group_G5_1_0	C0239849	Harlequin Fetus	3/50	73/21671	0.000641536162657742	0.00754703141750567	0.00399778324519351	BECN1/RELA/EPAS1	3
group_G5_1_0	C2945695	Limb ischemia	4/50	171/21671	0.000649539144225967	0.00761073555047238	0.00403152834327713	PIK3CB/MAPK3/MAPK14/EPAS1	4
group_G5_1_0	C0042963	Vomiting	5/50	303/21671	0.000654508174425463	0.00763852595629082	0.00404624936570462	RELA/PIK3CB/MAPK3/STK11/AP3B1	5
group_G5_1_0	C0265101	Carotid artery occlusion	3/50	74/21671	0.000667561171323862	0.0077295173419822	0.00409444895797479	BECN1/PIK3CB/MAPK14	3
group_G5_1_0	C3179349	Gastrointestinal Stromal Sarcoma	3/50	74/21671	0.000667561171323862	0.0077295173419822	0.00409444895797479	TSC1/PIK3CB/NPC1	3
group_G5_1_0	C1334274	Invasive Carcinoma	4/50	173/21671	0.000678447433791722	0.00773109515601162	0.00409528475130092	BECN1/PIK3CB/SRC/STAT1	4
group_G5_1_0	C0375023	Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site	6/50	467/21671	0.000690442584983308	0.00773109515601162	0.00409528475130092	BECN1/RELA/PRKAA1/MAPK14/STAT1/NFKB1	6
group_G5_1_0	C0019562	Von Hippel-Lindau Syndrome	4/50	174/21671	0.000693238589367412	0.00773109515601162	0.00409528475130092	PIK3CB/STK11/MUL1/EPAS1	4
group_G5_1_0	C0026706	Mucopolysaccharidosis III	2/50	17/21671	0.00069398474028802	0.00773109515601162	0.00409528475130092	TFEB/MAP1LC3A	2
group_G5_1_0	C0037899	Sphingolipidoses	2/50	17/21671	0.00069398474028802	0.00773109515601162	0.00409528475130092	BECN1/NPC1	2
group_G5_1_0	C0039841	Thiamine Deficiency	2/50	17/21671	0.00069398474028802	0.00773109515601162	0.00409528475130092	BECN1/PSEN1	2
group_G5_1_0	C0085261	Proteus Syndrome	2/50	17/21671	0.00069398474028802	0.00773109515601162	0.00409528475130092	TSC1/PIK3CB	2
group_G5_1_0	C0152264	Familial erythrocytosis	2/50	17/21671	0.00069398474028802	0.00773109515601162	0.00409528475130092	NFKB1/EPAS1	2
group_G5_1_0	C1367536	Nasopharyngeal Angiofibroma	2/50	17/21671	0.00069398474028802	0.00773109515601162	0.00409528475130092	HRAS/SRC	2
group_G5_1_0	C4749274	Chuvash erythrocytosis	2/50	17/21671	0.00069398474028802	0.00773109515601162	0.00409528475130092	MUL1/EPAS1	2
group_G5_1_0	C0020255	Hydrocephalus	6/50	473/21671	0.000737957840786175	0.00818993965944204	0.00433834202329112	HRAS/TSC1/MFN2/PSEN1/PIK3CB/IKBKB	6
group_G5_1_0	C0349639	Juvenile Myelomonocytic Leukemia	4/50	179/21671	0.000770642958806176	0.00846033979516754	0.00448157729982568	HRAS/PIK3CB/SRC/MUL1	4
group_G5_1_0	C0024301	Lymphoma, Follicular	6/50	477/21671	0.000771018554029553	0.00846033979516754	0.00448157729982568	HRAS/PMAIP1/PIK3CB/MAPK14/STAT1/BCL2L1	6
group_G5_1_0	C0020545	Hypertension, Renovascular	3/50	78/21671	0.000778376414323271	0.00846033979516754	0.00448157729982568	RELA/MAPK3/STAT1	3
group_G5_1_0	C1868684	EAR, PATELLA, SHORT STATURE SYNDROME	3/50	78/21671	0.000778376414323271	0.00846033979516754	0.00448157729982568	RELA/PSEN1/MAPK3	3
group_G5_1_0	C0740985	Acute anaemia	2/50	18/21671	0.000779582483675758	0.00846033979516754	0.00448157729982568	PRKAA1/STK11	2
group_G5_1_0	C1402291	Pigmented lesions	2/50	18/21671	0.000779582483675758	0.00846033979516754	0.00448157729982568	TFE3/HRAS	2
group_G5_1_0	C0520679	Sleep Apnea, Obstructive	6/50	480/21671	0.000796559322024928	0.00861279766939453	0.00456233667413658	HRAS/RELA/PRKAA1/PIK3CB/MAPK14/SRC	6
group_G5_1_0	C1527336	Sjogren's Syndrome	6/50	481/21671	0.000805217073167139	0.00867451799335002	0.00459503091685894	MFN2/RELA/PRKAA1/PIK3CB/STAT1/NFKB1	6
group_G5_1_0	C0021841	Intestinal Neoplasms	4/50	182/21671	0.000819915220097342	0.00880062285513242	0.00466183067900141	SGK1/PIK3CB/MAPK3/SRC	4
group_G5_1_0	C0016059	Fibrosis	4/50	184/21671	0.00085397522466539	0.00909978672369896	0.00482030256485422	SGK1/MAPK3/MAPK14/STAT1	4
group_G5_1_0	C0206663	Neuroectodermal Tumor, Primitive	4/50	184/21671	0.00085397522466539	0.00909978672369896	0.00482030256485422	HRAS/PIK3CB/SRC/STK11	4
group_G5_1_0	C0752308	Hypoxia-Ischemia, Brain	3/50	81/21671	0.00086872731308295	0.00921839195823737	0.00488312965450037	BECN1/MAP1LC3A/BCL2L1	3
group_G5_1_0	C1266042	Chromophobe Renal Cell Carcinoma	4/50	185/21671	0.000871374690374019	0.00921839195823737	0.00488312965450037	TFE3/TSC1/RELA/EPAS1	4
group_G5_1_0	C0032461	Polycythemia	3/50	82/21671	0.000900258482175113	0.00948982149131544	0.00502691021927624	NFKB1/BCL2L1/EPAS1	3
group_G5_1_0	C0035243	Respiratory Tract Infections	4/50	187/21671	0.000906922413391318	0.00952592434922809	0.00504603448052312	MFN2/PIK3CB/STAT1/IKBKB	4
group_G5_1_0	C0158252	Intervertebral disc disorder	4/50	188/21671	0.000925074618478686	0.00958917749365599	0.00507954068276485	RELA/PIK3CB/MAPK3/MAPK14	4
group_G5_1_0	C0243038	Carcinoma, Lewis Lung	4/50	188/21671	0.000925074618478686	0.00958917749365599	0.00507954068276485	CEBPB/MAPK3/MAPK14/EPAS1	4
group_G5_1_0	C0153382	Malignant neoplasm of oropharynx	3/50	83/21671	0.000932507569937304	0.00958917749365599	0.00507954068276485	PMAIP1/PIK3CB/NPC1	3
group_G5_1_0	C1709527	B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1	3/50	83/21671	0.000932507569937304	0.00958917749365599	0.00507954068276485	PIK3CB/SRC/NPC1	3
group_G5_1_0	C2118460	Acute colitis	3/50	83/21671	0.000932507569937304	0.00958917749365599	0.00507954068276485	RELA/PIK3CB/NFKB1	3
group_G5_1_0	C4020732	Mitochondrial abnormalities	3/50	83/21671	0.000932507569937304	0.00958917749365599	0.00507954068276485	TFEB/MFN2/PSEN1	3
group_G5_1_0	C4722099	High grade glioma	4/50	190/21671	0.000962145589096369	0.00969105659891847	0.00513350767422443	PIK3CB/MAPK3/STK11/EPAS1	4
group_G5_1_0	C0265319	Fibrous skin tumor of tuberous sclerosis	2/50	20/21671	0.000965258850792536	0.00969105659891847	0.00513350767422443	HRAS/TSC1	2
group_G5_1_0	C0338455	Dementia of frontal lobe type	2/50	20/21671	0.000965258850792536	0.00969105659891847	0.00513350767422443	PSEN1/HTRA2	2
group_G5_1_0	C1844384	Recurrent fungal infections	2/50	20/21671	0.000965258850792536	0.00969105659891847	0.00513350767422443	STAT1/IKBKB	2
group_G5_1_0	C1868678	THANATOPHORIC DYSPLASIA, TYPE I (disorder)	2/50	20/21671	0.000965258850792536	0.00969105659891847	0.00513350767422443	HRAS/STAT1	2
group_G5_1_0	C4324656	Non-squamous non-small cell lung cancer	2/50	20/21671	0.000965258850792536	0.00969105659891847	0.00513350767422443	PIK3CB/STK11	2
group_G5_1_0	C0039494	Temporomandibular Joint Disorders	3/50	84/21671	0.000965480987243493	0.00969105659891847	0.00513350767422443	BECN1/MAP1LC3A/NFKB1	3
group_G5_1_0	C0014869	Peptic Esophagitis	3/50	85/21671	0.000999185092320922	0.00996136731022316	0.00527669558121308	PIK3CB/MAPK14/EPAS1	3
group_G5_1_0	C0028326	Noonan Syndrome	3/50	85/21671	0.000999185092320922	0.00996136731022316	0.00527669558121308	HRAS/MAPK3/MUL1	3
group_G5_1_1	C1704380	Distal Renal Tubular Acidosis	3/10	23/21671	1.24700767408842e-07	1.53381943912876e-05	7.08825414744997e-06	ATP6V1B1/ATP6V0A4/ATP6AP1	3
group_G5_1_2	C1859736	Progressive spastic quadriplegia	2/9	12/21671	1.00972505468346e-05	0.00150044317526329	0.00059855537811301	ACP5/GM2A	2
group_G5_1_2	C0422895	Primitive reflex	2/9	14/21671	1.39159703169214e-05	0.00150044317526329	0.00059855537811301	CTSF/GM2A	2
group_G5_1_2	C1838319	Primitive reflexes (palmomental, snout, glabellar)	2/9	14/21671	1.39159703169214e-05	0.00150044317526329	0.00059855537811301	CTSF/GM2A	2
group_G5_1_2	C0085078	Lysosomal Storage Diseases	3/9	130/21671	1.72573102324212e-05	0.00150044317526329	0.00059855537811301	MAN2B1/ACP5/GBA	3
group_G5_1_2	C0022797	Adult Neuronal Ceroid Lipofuscinosis	2/9	16/21671	1.83428261034632e-05	0.00150044317526329	0.00059855537811301	CTSF/CLN5	2
group_G5_1_2	C0235946	Cerebral atrophy	4/9	454/21671	2.20348790955576e-05	0.00150204425834718	0.000599194080668671	CLN5/MAN2B1/GBA/GM2A	4
group_G5_1_2	C0039373	Tay-Sachs Disease	2/9	26/21671	4.95715875682509e-05	0.00289639704505923	0.00115542798091412	GBA/GM2A	2
group_G5_1_2	C0027066	Myoclonus	3/9	265/21671	0.000143814851877363	0.0073525343022302	0.00293306605802517	CTSF/CLN5/GBA	3
group_G5_1_2	C0027877	Neuronal Ceroid-Lipofuscinoses	2/9	51/21671	0.00019342851631543	0.00879025146366788	0.0035065988337885	CTSF/CLN5	2
group_G5_2_3	C0085078	Lysosomal Storage Diseases	6/7	130/21671	2.88945831067326e-13	7.22364577668316e-11	2.82862760939593e-11	CTNS/CHIT1/SGSH/MFSD8/NPC2/GNS	6
group_G5_2_3	C0262361	Growth abnormality	3/7	49/21671	3.77797099517597e-07	4.72246374396996e-05	1.84921738184929e-05	CTNS/SGSH/GNS	3
group_G5_2_3	C0038002	Splenomegaly	4/7	345/21671	2.12750333985628e-06	0.000177291944988023	6.94237931953102e-05	CTNS/SGSH/NPC2/GNS	4
group_G5_2_3	C0019214	Hepatosplenomegaly	3/7	127/21671	6.76248502496463e-06	0.000348209840465394	0.000136351642792765	CHIT1/SGSH/NPC2	3
group_G5_2_3	C0086648	MPS III B	2/7	13/21671	6.96419680930788e-06	0.000348209840465394	0.000136351642792765	SGSH/GNS	2
group_G5_2_3	C0026706	Mucopolysaccharidosis III	2/7	17/21671	1.21352307904757e-05	0.000483110062571097	0.000189175729764682	SGSH/GNS	2
group_G5_2_3	C1285162	Degenerative disorder	3/7	160/21671	1.35270817519907e-05	0.000483110062571097	0.000189175729764682	CHIT1/SGSH/MFSD8	3
group_G5_2_3	C0751072	Frontotemporal Lobar Degeneration	3/7	195/21671	2.44516814457131e-05	0.000668398926114668	0.000261730947910165	CHIT1/MFSD8/NPC2	3
group_G5_2_3	C0028064	Niemann-Pick Diseases	2/7	25/21671	2.67359570445867e-05	0.000668398926114668	0.000261730947910165	CHIT1/NPC2	2
group_G5_2_3	C0086647	Mucopolysaccharidosis Type IIIA	2/7	25/21671	2.67359570445867e-05	0.000668398926114668	0.000261730947910165	SGSH/GNS	2
group_G5_2_3	C0205700	Asymmetric Septal Hypertrophy	2/7	31/21671	4.1402484286585e-05	0.000900304805729536	0.000352540408138302	SGSH/GNS	2
group_G5_2_3	C0700201	Dyssomnias	3/7	236/21671	4.32146306750177e-05	0.000900304805729536	0.000352540408138302	SGSH/MFSD8/GNS	3
group_G5_2_3	C0086795	Pfaundler-Hurler Syndrome	2/7	36/21671	5.60505367837743e-05	0.00107789493814951	0.000422080965254333	SGSH/GNS	2
group_G5_2_3	C0023794	Lipoidosis	2/7	44/21671	8.40611941889056e-05	0.00150109275337331	0.000587796320268287	CHIT1/NPC2	2
group_G5_2_3	C0037317	Sleep disturbances	3/7	311/21671	9.81684130869564e-05	0.00156518658234305	0.000612894114349066	SGSH/MFSD8/GNS	3
group_G5_2_3	C0026703	Mucopolysaccharidoses	2/7	48/21671	0.000100171941269955	0.00156518658234305	0.000612894114349066	SGSH/GNS	2
group_G5_2_3	C0581381	Recurrent upper respiratory tract infection	2/7	52/21671	0.000117682820845147	0.00173062971831098	0.000677678163380721	SGSH/GNS	2
group_G5_2_3	C0851578	Sleep Disorders	3/7	360/21671	0.000151424941616216	0.00206440204749392	0.000808376380702884	SGSH/MFSD8/GNS	3
group_G5_2_3	C0277959	Coarse hair	2/7	60/21671	0.000156894555609538	0.00206440204749392	0.000808376380702884	SGSH/GNS	2
group_G5_2_3	C0011168	Deglutition Disorders	3/7	389/21671	0.000190391625463581	0.00237989531829476	0.000931916903584895	CTNS/NPC2/GNS	3
group_G5_2_3	C0019572	Hirsutism	2/7	88/21671	0.00033785763324338	0.00402211468146881	0.00157497543316463	SGSH/GNS	2
group_G5_2_3	C1962966	Retinopathy, CTCAE	2/7	108/21671	0.000508394845935041	0.00577721415835274	0.0022622354388497	CTNS/MFSD8	2
group_G5_2_3	C0431447	Synophrys	2/7	111/21671	0.000536918667810252	0.00583607247619839	0.00228528311699558	SGSH/GNS	2
group_G5_2_8	C0543874	Apraxia, oculomotor, Cogan type	1/2	10/21671	0.000922700696451506	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C1847164	Morning myoclonic jerks	1/2	11/21671	0.0010149473424329	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0334609	Hemangioblastic Meningioma	1/2	12/21671	0.00110718972956669	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0334610	Hemangiopericytic Meningioma	1/2	12/21671	0.00110718972956669	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0457190	Xanthomatous Meningioma	1/2	12/21671	0.00110718972956669	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0751303	Cerebral Convexity Meningioma	1/2	12/21671	0.00110718972956669	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C1334261	Intraorbital Meningioma	1/2	12/21671	0.00110718972956669	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C1335107	Olfactory Groove Meningioma	1/2	12/21671	0.00110718972956669	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C1384408	Microcystic meningioma	1/2	12/21671	0.00110718972956669	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C1527197	Angioblastic Meningioma	1/2	12/21671	0.00110718972956669	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C1565950	Posterior Fossa Meningioma	1/2	12/21671	0.00110718972956669	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0751304	Parasagittal Meningioma	1/2	13/21671	0.00119942785785232	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0431121	Clear Cell Meningioma	1/2	14/21671	0.00129166172729023	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0742034	cerebellar function	1/2	14/21671	0.00129166172729023	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C1565951	Sphenoid Wing Meningioma	1/2	14/21671	0.00129166172729023	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0334605	Meningothelial meningioma	1/2	15/21671	0.00138389133788019	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0334606	Fibrous Meningioma	1/2	15/21671	0.00138389133788019	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0334611	Transitional Meningioma	1/2	15/21671	0.00138389133788019	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C1334271	Intraventricular Meningioma	1/2	16/21671	0.00147611668962211	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C1384406	Secretory meningioma	1/2	16/21671	0.00147611668962211	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0205834	Meningiomas, Multiple	1/2	17/21671	0.00156833778251597	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C3163622	Papillary Meningioma	1/2	17/21671	0.00156833778251597	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0334608	Angiomatous Meningioma	1/2	18/21671	0.00166055461656223	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0014549	Tonic-Clonic Epilepsy	1/2	19/21671	0.00175276719176032	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0220669	Familial benign neonatal epilepsy	1/2	19/21671	0.00175276719176032	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0347515	Spinal Meningioma	1/2	19/21671	0.00175276719176032	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0520678	Postpartum psychosis	1/2	19/21671	0.00175276719176032	0.00655664764325156	NA	CSTB	1
group_G5_2_8	C0334607	Psammomatous Meningioma	1/2	22/21671	0.00202937936426761	0.00732026127825104	NA	CSTB	1
group_G5_2_8	C0270764	Motor Neuron Disease, Lower	1/2	23/21671	0.00212157490407427	0.00738893328660351	NA	CSTB	1
group_G5_2_8	C1849508	EPILEPSY, PYRIDOXINE-DEPENDENT	1/2	25/21671	0.00230595320714344	0.00776337579738292	NA	CSTB	1
group_G5_2_8	C4021757	EEG with polyspike wave complexes	1/2	30/21671	0.002766824434978	0.00901449251396058	NA	CSTB	1
group_G5_3_1	C0085078	Lysosomal Storage Diseases	9/10	130/21671	7.55328912338613e-20	4.41867413718089e-17	1.90024852683083e-17	GUSB/TPP1/SLC17A5/PPT1/MANBA/NPC2/SMPD1/AGA/FUCA1	9
group_G5_3_1	C0038002	Splenomegaly	7/10	345/21671	2.80979336405598e-11	8.21864558986375e-09	3.53442428425989e-09	GUSB/HGSNAT/SLC17A5/NPC2/SMPD1/AGA/FUCA1	7
group_G5_3_1	C1845847	Coarse facial features	6/10	194/21671	9.70930643551305e-11	1.89331475492505e-08	8.14219030907937e-09	GUSB/TPP1/HGSNAT/SLC17A5/AGA/FUCA1	6
group_G5_3_1	C0086795	Pfaundler-Hurler Syndrome	4/10	36/21671	1.33692373581329e-09	1.95525096362694e-07	8.40854665419413e-08	GUSB/HGSNAT/AGA/FUCA1	4
group_G5_3_1	C0002986	Fabry Disease	4/10	108/21671	1.19702784934968e-07	1.40052258373913e-05	6.02294012620155e-06	GUSB/MANBA/SMPD1/AGA	4
group_G5_3_1	C3806482	Recurrent respiratory infections	5/10	318/21671	1.56435611231263e-07	1.52524720950481e-05	6.55931773408278e-06	GUSB/MANBA/SMPD1/AGA/FUCA1	5
group_G5_3_1	C0542223	Loss of speech	3/10	37/21671	5.45252198242493e-07	4.55675051388369e-05	1.95962820120234e-05	HGSNAT/PPT1/NPC2	3
group_G5_3_1	C4021768	Abnormality of metabolism/homeostasis	4/10	171/21671	7.57454617354766e-07	5.53888688940672e-05	2.38199544141828e-05	SLC17A5/PPT1/MANBA/AGA	4
group_G5_3_1	C0235946	Cerebral atrophy	5/10	454/21671	9.1220992039648e-07	5.92936448257712e-05	2.54992012835975e-05	TPP1/SLC17A5/PPT1/AGA/FUCA1	5
group_G5_3_1	C4553743	Spasticity, CTCAE	5/10	477/21671	1.16391167197651e-06	6.80888328106258e-05	2.92815673265669e-05	SLC17A5/PPT1/NPC2/SMPD1/AGA	5
group_G5_3_1	C0019572	Hirsutism	3/10	88/21671	7.60592027408615e-06	0.00039130367300614	0.00016827994214749	GUSB/HGSNAT/FUCA1	3
group_G5_3_1	C1854718	J-shaped sella turcica	2/10	10/21671	8.60720028891022e-06	0.00039130367300614	0.00016827994214749	GUSB/SLC17A5	2
group_G5_3_1	C0020305	Hydrops Fetalis	3/10	92/21671	8.69563717791422e-06	0.00039130367300614	0.00016827994214749	GUSB/SLC17A5/NPC2	3
group_G5_3_1	C0162819	Skin Diseases, Vascular	2/10	11/21671	1.05173221472436e-05	0.000435824892877256	0.000187426269721393	AGA/FUCA1	2
group_G5_3_1	C0376480	Gingival Overgrowth	3/10	100/21671	1.1174997253263e-05	0.000435824892877256	0.000187426269721393	GUSB/SLC17A5/AGA	3
group_G5_3_1	C0851578	Sleep Disorders	4/10	360/21671	1.45324412042285e-05	0.000531342381529604	0.00022850351630333	HGSNAT/SLC17A5/PPT1/AGA	4
group_G5_3_1	C4732730	Blood spots	3/10	117/21671	1.79033742224264e-05	0.000616086701183497	0.000264947767130645	GUSB/PPT1/SMPD1	3
group_G5_3_1	C0022797	Adult Neuronal Ceroid Lipofuscinosis	2/10	16/21671	2.29186581201133e-05	0.000744856388903682	0.000320325104719712	TPP1/PPT1	2
group_G5_3_1	C0019187	Hepatitis, Alcoholic	3/10	133/21671	2.6278586657892e-05	0.000809103852361411	0.000347954693143279	SLC17A5/SMPD1/AGA	3
group_G5_3_1	C0019270	Hernia	3/10	136/21671	2.80909248359777e-05	0.000821659551452346	0.000353354265042035	HGSNAT/AGA/FUCA1	3
group_G5_3_1	C0022340	Late-Infantile Neuronal Ceroid Lipfuscinosis	2/10	19/21671	3.2634977496399e-05	0.000909117230256829	0.000390965394568389	TPP1/PPT1	2
group_G5_3_1	C1855685	Undetectable electroretinogram	2/10	21/21671	4.00583150510326e-05	0.001065187013857	0.000458083124267789	TPP1/PPT1	2
group_G5_3_1	C0268281	Infantile neuronal ceroid lipofuscinosis	2/10	22/21671	4.40533003821577e-05	0.00112048611841575	0.000481864475576004	TPP1/PPT1	2
group_G5_3_1	C0162298	Joint stiffness	3/10	163/21671	4.82244204029814e-05	0.00117547024732267	0.000505510371768095	GUSB/HGSNAT/AGA	3
group_G5_3_1	C0028064	Niemann-Pick Diseases	2/10	25/21671	5.71698410802709e-05	0.00133777428127834	0.000575309137607779	NPC2/SMPD1	2
group_G5_3_1	C1858452	Thickened calvaria	2/10	27/21671	6.68557889018471e-05	0.00150425525029156	0.000646904192208156	SLC17A5/AGA	2
group_G5_3_1	C0267971	Storage disease	2/10	28/21671	7.19808194071673e-05	0.00155958442048863	0.000670698473228577	GUSB/AGA	2
group_G5_3_1	C0333068	Flexion contracture	3/10	210/21671	0.000102377020764892	0.00213894846955221	0.000919853682812377	GUSB/PPT1/FUCA1	3
group_G5_3_1	C0016663	Pathological fracture	2/10	35/21671	0.000113108055376469	0.0022816624963874	0.00098122777622418	SMPD1/AGA	2
group_G5_3_1	C0007384	Cataplexy	2/10	36/21671	0.000119731990159078	0.00233477380810203	0.00100406826835157	SLC17A5/NPC2	2
group_G5_3_1	C0004158	Athetosis	2/10	39/21671	0.000140723653824666	0.00264378759670933	0.00113695948828345	SLC17A5/SMPD1	2
group_G5_3_1	C0700201	Dyssomnias	3/10	236/21671	0.000144617441187519	0.00264378759670933	0.00113695948828345	HGSNAT/PPT1/AGA	3
group_G5_3_1	C0241654	Abnormal heart valve morphology	2/10	42/21671	0.000163392186984197	0.0028964978601744	0.0012456374063548	GUSB/SMPD1	2
group_G5_3_1	C0026703	Mucopolysaccharidoses	2/10	48/21671	0.000213744871036028	0.00367766910459049	0.00158157969590126	GUSB/HGSNAT	2
group_G5_3_1	C0027877	Neuronal Ceroid-Lipofuscinoses	2/10	51/21671	0.000241421540229918	0.00396877586645024	0.00170677000824401	TPP1/PPT1	2
group_G5_3_1	C0581381	Recurrent upper respiratory tract infection	2/10	52/21671	0.000251016593262665	0.00396877586645024	0.00170677000824401	GUSB/HGSNAT	2
group_G5_3_1	C0751383	Juvenile Neuronal Ceroid Lipofuscinosis	2/10	52/21671	0.000251016593262665	0.00396877586645024	0.00170677000824401	TPP1/PPT1	2
group_G5_3_1	C0085605	Liver Failure	3/10	293/21671	0.000273613476156119	0.0042122074618771	0.00181145763992555	SLC17A5/NPC2/SMPD1	3
group_G5_3_1	C0042963	Vomiting	3/10	303/21671	0.000301961316982586	0.00452941975473879	0.0019478746223708	SLC17A5/PPT1/SMPD1	3
group_G5_3_1	C0241210	Speech Delay	2/10	58/21671	0.000312456961833944	0.00454020229216545	0.00195251164701312	GUSB/TPP1	2
group_G5_3_1	C1859236	Prolonged neonatal jaundice	2/10	59/21671	0.000323340744812997	0.00454020229216545	0.00195251164701312	NPC2/SMPD1	2
group_G5_3_1	C0037317	Sleep disturbances	3/10	311/21671	0.000325963241488801	0.00454020229216545	0.00195251164701312	HGSNAT/PPT1/AGA	3
group_G5_3_1	C0008073	Developmental Disabilities	3/10	355/21671	0.000480211380653048	0.00653310831818682	0.00280955985253558	TPP1/SLC17A5/PPT1	3
group_G5_3_1	C1839364	Progressive visual loss	2/10	77/21671	0.000550503382298523	0.007319192696469	0.0031476150327595	TPP1/PPT1	2
group_G5_3_1	C1853241	Flat face	2/10	83/21671	0.000639301916871905	0.00831092491933477	0.00357410896216106	GUSB/TPP1	2
group_G5_3_1	C1840077	Anteverted nostril	3/10	407/21671	0.000715297453632623	0.00909671761684966	0.0039120387052219	HGSNAT/SLC17A5/AGA	3
group_G5_3_1	C1844704	Platyspondyly	2/10	93/21671	0.000801706590829783	0.00997868841777496	0.00429132979189962	GUSB/AGA	2
group_G5_3_7	C0259785	Malignant Meningioma	2/3	49/21671	1.50034890339929e-05	0.00421598041855199	0.000600139561359714	DAB2/CST3	2
group_G5_3_7	C0546126	Acute Confusional Senile Dementia	2/3	99/21671	6.17940502038998e-05	0.00578804270243195	0.00082392066938533	CST3/PICALM	2
group_G5_3_7	C0750900	Alzheimer's Disease, Focal Onset	2/3	99/21671	6.17940502038998e-05	0.00578804270243195	0.00082392066938533	CST3/PICALM	2
group_G5_3_7	C0026998	Acute Myeloid Leukemia, M1	2/3	138/21671	0.000120271318726663	0.00725865280015859	0.00103326018507596	CST3/PICALM	2
group_G5_3_7	C1879321	Acute Myeloid Leukemia (AML-M2)	2/3	143/21671	0.000129157523134495	0.00725865280015859	0.00103326018507596	CST3/PICALM	2
group_G5_3_7	C0750901	Alzheimer Disease, Early Onset	2/3	174/21671	0.000191282160290968	0.00785617677264392	0.0011183169783123	CST3/PICALM	2
group_G5_3_7	C0038868	Progressive supranuclear palsy	2/3	176/21671	0.000195705471204653	0.00785617677264392	0.0011183169783123	CST3/PICALM	2
group_G5_4_1	C0008711	Chronic rhinitis	2/12	15/21671	2.9395993940882e-05	0.00864242221861931	0.00457958642447425	SLC29A3/TCIRG1	2
group_G5_4_6	C0026707	Mucopolysaccharidosis IV	2/3	28/21671	4.82567033228379e-06	0.000361925274921284	3.04779178881082e-05	HYAL1/ARSB	2
group_G5_4_6	C0026703	Mucopolysaccharidoses	2/3	48/21671	1.43915451230823e-05	0.000539682942115585	4.54469845992072e-05	HYAL1/ARSB	2
group_G5_4_6	C0085078	Lysosomal Storage Diseases	2/3	130/21671	0.000106709432320245	0.00266773580800614	0.000224651436463675	HYAL1/ARSB	2
group_G5_5_0	C1739395	Takotsubo Cardiomyopathy	5/47	44/21671	3.92869319082151e-08	9.77065996557309e-05	6.05432298038178e-05	PPARGC1A/TLR4/NOX4/BAG3/ESR1	5
group_G5_5_0	C3241937	Nonalcoholic Steatohepatitis	9/47	434/21671	3.31231395171466e-07	0.000411886239895718	0.000255222506595277	PPARGC1A/TLR4/E2F1/XBP1/PRKACA/RAB5A/MAPK14/SREBF2/ESR1	9
group_G5_5_0	C0011882	Diabetic Neuropathies	6/47	144/21671	6.65191739102152e-07	0.000551443951715684	0.000341698493349316	PPARGC1A/TLR4/BECN1/MAPK14/NOX4/FOXO3	6
group_G5_5_0	C3714514	Infection	9/47	491/21671	9.27116805532507e-07	0.000552381927109213	0.000342279703421111	TLR4/E2F1/MAPK14/ABL1/SP1/HDAC6/BAG3/RPTOR/ESR1	9
group_G5_5_0	C0014335	Enteritis	5/47	85/21671	1.1105386552256e-06	0.000552381927109213	0.000342279703421111	TLR4/BECN1/XBP1/JUNB/MAPK14	5
group_G5_5_0	C0018081	Gonorrhea	7/47	261/21671	1.4138996089951e-06	0.000562758298701481	0.000348709351490474	PPARGC1A/TLR4/BECN1/E2F1/ABL1/HDAC6/ESR1	7
group_G5_5_0	C0008479	Chondrosarcoma	8/47	385/21671	1.58395982746697e-06	0.000562758298701481	0.000348709351490474	BECN1/SESN2/JUNB/MAP1LC3B/MAPK14/HDAC6/BAG3/ESR1	8
group_G5_5_0	C0282160	Aplasia Cutis Congenita	8/47	393/21671	1.84604737082207e-06	0.000573889976404312	0.000355607019853094	TLR4/BECN1/E2F1/PRKACA/SESN2/JUNB/FOXO3/ESR1	8
group_G5_5_0	C0376618	Endotoxemia	8/47	401/21671	2.14424565826709e-06	0.000587757360573286	0.000364199850117153	TLR4/SIRT2/JUNB/MAPK14/HDAC6/NOX4/SIRT5/ATF3	8
group_G5_5_0	C0162557	Liver Failure, Acute	7/47	282/21671	2.3633186995307e-06	0.000587757360573286	0.000364199850117153	TLR4/BECN1/SIRT2/SESN2/HDAC6/FOXO3/ESR1	7
group_G5_5_0	C0041341	Tuberous Sclerosis	7/47	289/21671	2.77922907491412e-06	0.000628358428119219	0.000389358025423375	CLN3/RHEB/MAPK14/ABL1/NOX4/NPC1/RPTOR	7
group_G5_5_0	C0162309	Adrenoleukodystrophy	7/47	294/21671	3.11236583316521e-06	0.00064503781892349	0.000399693296469637	TLR4/BECN1/RHEB/XBP1/MAPK14/NOX4/FOXO3	7
group_G5_5_0	C0035126	Reperfusion Injury	7/47	300/21671	3.555556064211e-06	0.000680205225514827	0.000421484540729142	TLR4/BECN1/MAPK14/AKT1S1/NOX4/BAG3/ATF3	7
group_G5_5_0	C2937421	Prostatic Hyperplasia	5/47	112/21671	4.34808659647821e-06	0.000772406526102951	0.00047861644941685	TLR4/LGALS8/MAPK14/ATF3/ESR1	5
group_G5_5_0	C2349952	Oropharyngeal Carcinoma	5/47	115/21671	4.95030255192756e-06	0.000820760163109589	0.000508578451650663	TLR4/E2F1/XBP1/NPC1/ESR1	5
group_G5_5_0	C0010823	Cytomegalovirus Infections	8/47	462/21671	6.08860477448797e-06	0.000890727063185387	0.000551932965315814	TLR4/E2F1/JUNB/MAPK14/SREBF2/SP1/FOXO3/ESR1	8
group_G5_5_0	C0349566	Squamous cell carcinoma of tongue	8/47	462/21671	6.08860477448797e-06	0.000890727063185387	0.000551932965315814	BECN1/E2F1/PXN/MAP1LC3B/ABL1/SP1/NOX4/ATF3	8
group_G5_5_0	C0853879	Invasive carcinoma of breast	8/47	473/21671	7.23050737793408e-06	0.000999015102717892	0.000619032912356462	TLR4/BECN1/PXN/MAP1LC3B/MAPK14/HDAC6/FOXO3/ESR1	8
group_G5_5_0	C0158266	Intervertebral Disc Degeneration	7/47	342/21671	8.38313075127317e-06	0.00101146729552119	0.000626748828917964	PPARGC1A/TLR4/BECN1/SIRT2/JUNB/MAPK14/FOXO3	7
group_G5_5_0	C0442874	Neuropathy	8/47	484/21671	8.54890336475998e-06	0.00101146729552119	0.000626748828917964	PPARGC1A/TLR4/MAPK14/AMBRA1/HDAC6/BAG3/ATF3/ESR1	8
group_G5_5_0	C0276138	Viral myocarditis	5/47	129/21671	8.67905987160009e-06	0.00101146729552119	0.000626748828917964	PPARGC1A/MAPK14/SP1/NOX4/FOXO3	5
group_G5_5_0	C0020443	Hypercholesterolemia	8/47	489/21671	9.21228103524894e-06	0.00101146729552119	0.000626748828917964	TLR4/BECN1/E2F1/SREBF2/NOX4/NPC1/ATF3/ESR1	8
group_G5_5_0	C0920646	Ischemia of kidney	5/47	131/21671	9.35414065017589e-06	0.00101146729552119	0.000626748828917964	TLR4/SIRT2/MAPK14/FOXO3/ATF3	5
group_G5_5_0	C4733092	estrogen receptor-negative breast cancer	7/47	356/21671	1.08782430177569e-05	0.00112725793271506	0.000698497709561233	TLR4/E2F1/PXN/MAPK14/SP1/HDAC6/ESR1	7
group_G5_5_0	C0949664	Tauopathies	6/47	245/21671	1.43062550167817e-05	0.00142318624906944	0.000881867677666037	PPARGC1A/TLR4/MAPK14/SP1/HDAC6/NPC1	6
group_G5_5_0	C2752147	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C	4/47	69/21671	1.51383186763448e-05	0.00144803840569498	0.000897267147456226	CUL4A/USP11/MAPK14/ESR1	4
group_G5_5_0	C0003504	Aortic Valve Insufficiency	7/47	377/21671	1.57552165466267e-05	0.00145123050190595	0.000899245108158341	TLR4/PXN/JUNB/MAP1LC3B/MAPK14/HDAC6/ESR1	7
group_G5_5_0	C0751075	Cancer of Digestive System	4/47	71/21671	1.69604659485077e-05	0.00150645281478352	0.000933463238669747	PPARGC1A/TLR4/PIK3R2/NOX4	4
group_G5_5_0	C3873567	Peripheral neuropathy due to and following chemotherapy	4/47	72/21671	1.79296840567446e-05	0.00153762497410772	0.000952778855138808	TLR4/RPS6KB2/MAPK14/HDAC6	4
group_G5_5_0	C0028064	Niemann-Pick Diseases	3/47	25/21671	2.1265072550076e-05	0.0017628745144013	0.00109235320046706	TLR4/SREBF2/NPC1	3
group_G5_5_0	C0162770	Right Ventricular Hypertrophy	5/47	160/21671	2.46062595504539e-05	0.00191236773443684	0.00118498565729818	PPARGC1A/TLR4/SESN2/MAPK14/NOX4	5
group_G5_5_0	C4733095	HER2-negative breast cancer	5/47	160/21671	2.46062595504539e-05	0.00191236773443684	0.00118498565729818	E2F1/XBP1/SESN2/FOXO3/ESR1	5
group_G5_5_0	C0282687	Hemorrhagic Fever, Ebola	5/47	164/21671	2.7703497725941e-05	0.0020682539187176	0.00128157947093415	TLR4/JUNB/NPC1/BAG3/ESR1	5
group_G5_5_0	C2973725	Pulmonary arterial hypertension	7/47	413/21671	2.82752847753913e-05	0.0020682539187176	0.00128157947093415	PPARGC1A/XBP1/SESN2/PXN/HDAC6/NOX4/ESR1	7
group_G5_5_0	C0003486	Aortic Aneurysm	6/47	278/21671	2.91545093528138e-05	0.0020716361360128	0.00128367523887277	TLR4/XBP1/MAP1LC3B/MAPK14/NOX4/ESR1	6
group_G5_5_0	C0003130	Anoxia	6/47	287/21671	3.484332817335e-05	0.00240709325464226	0.00149153896040305	TLR4/PRKACA/MAPK14/SP1/NOX4/ESR1	6
group_G5_5_0	C0240066	Iron deficiency	5/47	179/21671	4.21038719315207e-05	0.00283006295928898	0.00175362926053332	PPARGC1A/CLN3/SIRT2/MAPK14/ESR1	5
group_G5_5_0	C0023440	Acute Erythroblastic Leukemia	6/47	302/21671	4.62831126257327e-05	0.00295143848974865	0.00182883878229616	STK38/BECN1/E2F1/RPS6KB2/ABL1/ESR1	6
group_G5_5_0	C1847835	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding)	6/47	302/21671	4.62831126257327e-05	0.00295143848974865	0.00182883878229616	TLR4/XBP1/MAPK14/SP1/FOXO3/ESR1	6
group_G5_5_0	C0947751	Vascular inflammations	6/47	305/21671	4.88963982892818e-05	0.00298553965153145	0.00184996933521345	PPARGC1A/TLR4/JUNB/NOX4/FOXO3/ESR1	6
group_G5_5_0	C4721773	Postoperative cognitive dysfunction	4/47	93/21671	4.92187879826255e-05	0.00298553965153145	0.00184996933521345	PPARGC1A/TLR4/BECN1/BAG3	4
group_G5_5_0	C1969372	Tubulointerstitial fibrosis	6/47	328/21671	7.31137522222052e-05	0.00431982199881215	0.00267674831492646	PPARGC1A/TLR4/CUL3/SIRT2/SESN2/MAPK14	6
group_G5_5_0	C0521607	Peritoneal Fibrosis	4/47	104/21671	7.61725701375368e-05	0.00431982199881215	0.00267674831492646	TLR4/XBP1/MAPK14/HDAC6	4
group_G5_5_0	C0856742	Post MI	5/47	203/21671	7.64940108435132e-05	0.00431982199881215	0.00267674831492646	PPARGC1A/TLR4/E2F1/MAPK14/FOXO3	5
group_G5_5_0	C0085281	Addictive Behavior	6/47	332/21671	7.81632448518484e-05	0.00431982199881215	0.00267674831492646	TLR4/E2F1/ABL1/HDAC6/BAG3/ESR1	6
group_G5_5_0	C1391732	Cancer cachexia	4/47	110/21671	9.47338881138736e-05	0.00512180825520008	0.0031736936429911	TLR4/XBP1/MAPK14/FOXO3	4
group_G5_5_0	C0333516	Tumor necrosis	6/47	350/21671	0.000104446680842244	0.00548837944625298	0.00340083698783754	TLR4/BECN1/XBP1/NOX4/NPC1/ESR1	6
group_G5_5_0	C0577631	Carotid Atherosclerosis	5/47	219/21671	0.000109330126592879	0.00548837944625298	0.00340083698783754	PPARGC1A/TLR4/MAP1LC3B/SREBF2/ESR1	5
group_G5_5_0	C0858252	Breast adenocarcinoma	5/47	219/21671	0.000109330126592879	0.00548837944625298	0.00340083698783754	BECN1/PXN/MAP1LC3B/MAPK14/ESR1	5
group_G5_5_0	C0221406	Pituitary-dependent Cushing's disease	4/47	115/21671	0.000112548191298312	0.00548837944625298	0.00340083698783754	E2F1/PRKACA/ABL1/SP1	4
group_G5_5_0	C1275685	Avellino corneal dystrophy	4/47	115/21671	0.000112548191298312	0.00548837944625298	0.00340083698783754	TLR4/XBP1/JUNB/MAPK14	4
group_G5_5_0	C0574143	Liver calculus	3/47	45/21671	0.000127265371465957	0.0058086370685369	0.00359928244485558	TLR4/BECN1/MAPK14	3
group_G5_5_0	C0037286	Skin Neoplasms	6/47	363/21671	0.000127473995820595	0.0058086370685369	0.00359928244485558	E2F1/USP11/XBP1/MAPK14/SP1/HDAC6	6
group_G5_5_0	C0014057	Japanese Encephalitis	4/47	119/21671	0.000128457997092694	0.0058086370685369	0.00359928244485558	XBP1/SESN2/RAB5A/ATF3	4
group_G5_5_0	C3805278	Extrahepatic Cholangiocarcinoma	4/47	119/21671	0.000128457997092694	0.0058086370685369	0.00359928244485558	BECN1/PRKACA/MAPK14/FOXO3	4
group_G5_5_0	C0027022	Myeloproliferative disease	6/47	365/21671	0.000131348874720096	0.00583329734694428	0.00361456301861318	TLR4/JUNB/MAPK14/ABL1/HDAC6/FOXO3	6
group_G5_5_0	C0346957	Disseminated Malignant Neoplasm	5/47	232/21671	0.000143210841759753	0.00622994891540555	0.00386034546469165	XBP1/RAB5A/MAPK14/FOXO3/ESR1	5
group_G5_5_0	C0034494	Rabies (disorder)	4/47	123/21671	0.00014593827173475	0.00622994891540555	0.00386034546469165	RAB5A/PIK3R2/HDAC6/ESR1	4
group_G5_5_0	C0242422	Parkinsonian Disorders	6/47	373/21671	0.000147795330120196	0.00622994891540555	0.00386034546469165	BECN1/CLN3/SIRT2/ABL1/NPC1/ESR1	6
group_G5_5_0	C3665339	Bacterial sepsis of newborn	3/47	48/21671	0.000154416382927513	0.00632354617091769	0.0039183423673517	TLR4/MAPK14/HDAC6	3
group_G5_5_0	C2347748	Adult Erythroleukemia	5/47	236/21671	0.000155101052041005	0.00632354617091769	0.0039183423673517	STK38/BECN1/E2F1/RPS6KB2/ABL1	5
group_G5_5_0	C4520840	Erythroleukemia (Erythroid/Myeloid)	5/47	237/21671	0.00015818833776431	0.00634539348419094	0.00393187990639982	STK38/BECN1/E2F1/RPS6KB2/ABL1	5
group_G5_5_0	C0282193	Iron Overload	5/47	241/21671	0.000171010775421518	0.00661273985304632	0.0040975392651725	TLR4/SESN2/MAPK14/NOX4/FOXO3	5
group_G5_5_0	C0867389	Chronic graft-versus-host disease	5/47	241/21671	0.000171010775421518	0.00661273985304632	0.0040975392651725	BECN1/XBP1/ATG10/MAPK14/ABL1	5
group_G5_5_0	C1851841	ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1	4/47	129/21671	0.000175301735478644	0.00661273985304632	0.0040975392651725	ATG10/SESN2/MAPK14/ESR1	4
group_G5_5_0	C0494463	Alzheimer Disease, Late Onset	6/47	385/21671	0.000175488874266609	0.00661273985304632	0.0040975392651725	PPARGC1A/TLR4/SIRT2/SREBF2/NPC1/ESR1	6
group_G5_5_0	C0598608	Hyperhomocysteinemia	5/47	246/21671	0.000188140255408496	0.0069016807437856	0.00427657952252857	PPARGC1A/TLR4/XBP1/MAP1LC3B/ATF3	5
group_G5_5_0	C1290884	Inflammatory disorder	6/47	391/21671	0.000190797097897677	0.0069016807437856	0.00427657952252857	TLR4/HYAL2/XBP1/MAPK14/FOXO3/ESR1	6
group_G5_5_0	C0023892	Biliary cirrhosis	4/47	132/21671	0.000191482095424691	0.0069016807437856	0.00427657952252857	PPARGC1A/TLR4/MAPK14/ESR1	4
group_G5_5_0	C0042900	Vitiligo	6/47	395/21671	0.000201576553358252	0.00701448673381515	0.00434647898686026	TLR4/XBP1/MAPK14/SP1/FOXO3/ESR1	6
group_G5_5_0	C0006131	Branchioma	2/47	10/21671	0.000204889272094406	0.00701448673381515	0.00434647898686026	NPC1/ESR1	2
group_G5_5_0	C0042131	Uterine Diseases	2/47	10/21671	0.000204889272094406	0.00701448673381515	0.00434647898686026	TLR4/ESR1	2
group_G5_5_0	C0456103	Sepsis of the newborn	3/47	53/21671	0.000207561340545343	0.00701448673381515	0.00434647898686026	TLR4/MAPK14/HDAC6	3
group_G5_5_0	C0008373	Cholesteatoma	4/47	135/21671	0.000208714120748822	0.00701448673381515	0.00434647898686026	TLR4/BECN1/SESN2/MAPK14	4
group_G5_5_0	C0231341	Premature aging syndrome	4/47	136/21671	0.000214698721424337	0.00711940960243103	0.00441149372863481	PPARGC1A/CUL4A/SIRT2/FOXO3	4
group_G5_5_0	C2936719	Mechanical Allodynia	6/47	408/21671	0.000239977455722	0.00785294647869228	0.00486602486394747	TLR4/RPS6KB2/SIRT2/MAPK14/SP1/HDAC6	6
group_G5_5_0	C4546431	Exacerbation of allergic asthma	2/47	11/21671	0.000250073908535875	0.00807706247439898	0.00500489681608368	XBP1/MAPK14	2
group_G5_5_0	C0036472	Scrub Typhus	3/47	58/21671	0.000271324928492552	0.00865109098924329	0.00536058968033868	TLR4/JUNB/MAPK14	3
group_G5_5_0	C0008370	Cholestasis	6/47	420/21671	0.000280345232947815	0.00882555182710399	0.00546869315170687	PPARGC1A/E2F1/MAPK14/NOX4/NPC1/ESR1	6
group_G5_5_0	C1563937	Atherogenesis	3/47	59/21671	0.0002854264162127	0.00887319371401232	0.00549821412283412	TLR4/NPC1/ESR1	3
group_G5_5_0	C0410808	Prosthetic joint infection	2/47	12/21671	0.000299673747333225	0.00908888548314305	0.00563186606028038	TLR4/ESR1	2
group_G5_5_0	C0877104	Retinal toxicity	2/47	12/21671	0.000299673747333225	0.00908888548314305	0.00563186606028038	CLN3/ESR1	2
group_G5_5_0	C3665444	Neutrophilia (disorder)	4/47	150/21671	0.00031205873410649	0.00935048279184145	0.00579396305303616	TLR4/BECN1/ABL1/ESR1	4
group_G5_5_0	C1737250	Progression of non-small cell lung cancer	4/47	151/21671	0.000320043447108818	0.00947557205904321	0.00587147376650764	E2F1/PIK3R2/NOX4/ESR1	4
group_G5_5_0	C2750440	FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1	3/47	63/21671	0.000346548287094215	0.00956062927418343	0.00592417889124692	PPARGC1A/TLR4/SIRT2	3
group_G5_5_0	C2750441	LIVER DISEASE, ALCOHOLIC, SUSCEPTIBILITY TO, 1	3/47	63/21671	0.000346548287094215	0.00956062927418343	0.00592417889124692	PPARGC1A/TLR4/SIRT2	3
group_G5_5_0	C3150651	FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2	3/47	63/21671	0.000346548287094215	0.00956062927418343	0.00592417889124692	PPARGC1A/TLR4/SIRT2	3
group_G5_5_0	C0206686	Adrenocortical carcinoma	5/47	281/21671	0.000347574468393214	0.00956062927418343	0.00592417889124692	E2F1/PRKACA/MAPK14/ATF3/ESR1	5
group_G5_5_0	C0242917	Filoviridae Infections	2/47	13/21671	0.000353670242551217	0.00956062927418343	0.00592417889124692	TLR4/NPC1	2
group_G5_5_0	C0278952	Nasopharyngeal cancer recurrent	2/47	13/21671	0.000353670242551217	0.00956062927418343	0.00592417889124692	NOX4/NPC1	2
group_G5_5_0	C0405581	Testicular dysfunction	2/47	13/21671	0.000353670242551217	0.00956062927418343	0.00592417889124692	TLR4/ESR1	2
group_G5_5_0	C4688316	Refractory Breast Carcinoma	2/47	13/21671	0.000353670242551217	0.00956062927418343	0.00592417889124692	SP1/ESR1	2
group_G5_5_0	C0027059	Myocarditis	5/47	285/21671	0.000370816347976886	0.00991634685396252	0.00614459686970188	TLR4/MAPK14/NOX4/FOXO3/ESR1	5
group_G5_5_1	C0001126	Renal tubular acidosis	3/12	52/21671	2.82329729102392e-06	0.0011095558353724	0.000573575133860649	EPG5/ATP6V0A2/ATP6V1B1	3
group_G5_5_2	C0267971	Storage disease	3/9	28/21671	1.61414292233204e-07	3.53497299990717e-05	1.76706172550034e-05	CTSA/HEXB/LIPA	3
group_G5_5_2	C0085078	Lysosomal Storage Diseases	3/9	130/21671	1.72573102324212e-05	0.00188967547045012	0.000944610665353582	CTSA/HEXB/LIPA	3
group_G5_5_2	C1845847	Coarse facial features	3/9	194/21671	5.70290629424755e-05	0.00416312159480071	0.00208106054246226	CTSA/HEXB/NAGA	3
group_G5_5_2	C0423250	Corneal stromal opacities	2/9	46/21671	0.000157187689821258	0.00860602601771385	0.00430197887931863	CTSA/NAGA	2
group_G5_6_0	C0338508	Optic Atrophy 1	7/50	117/21671	9.19458269837074e-09	2.56253019803593e-05	1.47113323173932e-05	KEAP1/OPTN/BNIP3L/PRKAB1/DNM1L/NFE2L1/SIRT3	7
group_G5_6_0	C4551683	Adrenal Gland Pheochromocytoma	10/50	416/21671	3.15823779765166e-08	4.15278388825726e-05	2.38408834632638e-05	HIF1A/TGM2/EGF/RPS6KB1/PRKAB1/DNM1L/KRAS/MAPK8/STAT3/ATF4	10
group_G5_6_0	C3898877	hormone-resistant prostate cancer	4/50	16/21671	4.47016564936196e-08	4.15278388825726e-05	2.38408834632638e-05	HIF1A/EGF/EGR1/STAT3	4
group_G5_6_0	C1318485	Liver regeneration disorder	9/50	346/21671	8.55618282615267e-08	5.86176111893803e-05	3.36520193408714e-05	HIF1A/KEAP1/EGF/EGR1/PRKAB1/KRAS/MAPK8/STAT3/NEDD4	9
group_G5_6_0	C1262048	Glial scar	5/50	51/21671	1.15441854946688e-07	5.86176111893803e-05	3.36520193408714e-05	HIF1A/EGR1/RAB7A/STAT3/SIRT3	5
group_G5_6_0	C0021670	insulinoma	8/50	258/21671	1.26195072528268e-07	5.86176111893803e-05	3.36520193408714e-05	TGM2/EGF/EGR1/YY1/MAPK8/NEDD4/NFE2L1/RAB8A	8
group_G5_6_0	C0004135	Ataxia Telangiectasia	9/50	384/21671	2.06892230974319e-07	7.77839502642253e-05	4.46552997570005e-05	HIF1A/TGM2/CUL5/EGF/YY1/PRKDC/KRAS/STAT3/FLCN	9
group_G5_6_0	C0003486	Aortic Aneurysm	8/50	278/21671	2.23276498785003e-07	7.77839502642253e-05	4.46552997570005e-05	HIF1A/EGF/EGR1/KRAS/MAPK8/STAT3/HDAC5/FOXO4	8
group_G5_6_0	C0041341	Tuberous Sclerosis	8/50	289/21671	2.99971077571284e-07	9.28910436879077e-05	5.33281915682283e-05	EGF/RPS6KB1/PRKAB1/PIK3C3/KRAS/STAT3/FLCN/WDR45B	8
group_G5_6_0	C4049446	Neointimal hyperplasia	7/50	198/21671	3.42361499834846e-07	9.54161500039715e-05	5.47778399735753e-05	HIF1A/TGM2/DAPK1/PRKAB1/AKT1S1/STAT3/SIRT3	7
group_G5_6_0	C0035126	Reperfusion Injury	8/50	300/21671	3.9824627146026e-07	0.000100901123505431	5.79267303942196e-05	HIF1A/KEAP1/EGF/EGR1/MAPK8/AKT1S1/STAT3/HSPA1A	8
group_G5_6_0	C0011644	Scleroderma	8/50	316/21671	5.89809332130309e-07	0.000136983217387264	7.86412442840412e-05	HIF1A/EGF/EGR1/YY1/SMURF1/KRAS/STAT3/HDAC5	8
group_G5_6_0	C0238462	Medullary carcinoma of thyroid	8/50	330/21671	8.17401902278686e-07	0.000175238392434669	0.000100603311049684	HIF1A/TGM2/LAMTOR1/EGF/KRAS/STAT3/FLCN/ATF4	8
group_G5_6_0	C4525297	Stage 0 Gallbladder Cancer AJCC v8	8/50	367/21671	1.80938053935127e-06	0.000280152420176222	0.000160833825720113	HIF1A/KEAP1/TGM2/EGF/KRAS/MAPK8/AKT1S1/STAT3	8
group_G5_6_0	C4525300	Stage IIA Gallbladder Cancer AJCC v8	8/50	367/21671	1.80938053935127e-06	0.000280152420176222	0.000160833825720113	HIF1A/KEAP1/TGM2/EGF/KRAS/MAPK8/AKT1S1/STAT3	8
group_G5_6_0	C4525301	Stage IIB Gallbladder Cancer AJCC v8	8/50	367/21671	1.80938053935127e-06	0.000280152420176222	0.000160833825720113	HIF1A/KEAP1/TGM2/EGF/KRAS/MAPK8/AKT1S1/STAT3	8
group_G5_6_0	C4525302	Stage III Gallbladder Cancer AJCC v8	8/50	367/21671	1.80938053935127e-06	0.000280152420176222	0.000160833825720113	HIF1A/KEAP1/TGM2/EGF/KRAS/MAPK8/AKT1S1/STAT3	8
group_G5_6_0	C4525305	Stage IV Gallbladder Cancer AJCC v8	8/50	367/21671	1.80938053935127e-06	0.000280152420176222	0.000160833825720113	HIF1A/KEAP1/TGM2/EGF/KRAS/MAPK8/AKT1S1/STAT3	8
group_G5_6_0	C0279671	Cervical Squamous Cell Carcinoma	8/50	371/21671	1.96127468258269e-06	0.000287688028439893	0.000165159973270122	HIF1A/KEAP1/DAPK1/USP8/YY1/KRAS/STAT3/SIRT3	8
group_G5_6_0	C0235874	Disease Exacerbation	6/50	166/21671	2.21837850725425e-06	0.00030913104498588	0.00017747028058034	HIF1A/KEAP1/EGF/YY1/PRKAB1/KRAS	6
group_G5_6_0	C0032000	Pituitary Adenoma	6/50	170/21671	2.54681066371482e-06	0.000337998158084439	0.000194042717235415	HIF1A/EGF/USP8/KRAS/MAPK8/STAT3	6
group_G5_6_0	C0282160	Aplasia Cutis Congenita	8/50	393/21671	3.00575022335063e-06	0.000380773903294463	0.000218600016243682	HIF1A/EGF/DAPK1/RPS6KB1/PRKAB1/KRAS/MAPK8/STAT3	8
group_G5_6_0	C0265219	Miller Dieker syndrome	6/50	182/21671	3.77770335369107e-06	0.000457759097684218	0.000262796755039379	HIF1A/DAPK1/YY1/KRAS/MAPK8/STAT3	6
group_G5_6_0	C0026277	Mixed Salivary Gland Tumor	6/50	185/21671	4.15098470520789e-06	0.000480740235700081	0.000275990088668866	HIF1A/KEAP1/EGF/DAPK1/KRAS/STAT3	6
group_G5_6_0	C2973725	Pulmonary arterial hypertension	8/50	413/21671	4.33350729567004e-06	0.000480740235700081	0.000275990088668866	HIF1A/EGR1/SMURF1/PRKAB1/PIK3C3/DNM1L/KRAS/SIRT3	8
group_G5_6_0	C0699753	Cancer Relapse	4/50	48/21671	4.52634793591056e-06	0.000480740235700081	0.000275990088668866	HIF1A/ULK1/KRAS/STAT3	4
group_G5_6_0	C0153633	Malignant neoplasm of brain	7/50	294/21671	4.77421128068313e-06	0.000480740235700081	0.000275990088668866	HIF1A/TGM2/EGF/DAPK1/KRAS/STAT3/HSPA1A	7
group_G5_6_0	C0022665	Kidney Neoplasm	7/50	295/21671	4.88172935561314e-06	0.000480740235700081	0.000275990088668866	HIF1A/TGM2/EGF/KRAS/AKT1S1/SIRT3/FLCN	7
group_G5_6_0	C0685938	Malignant neoplasm of gastrointestinal tract	8/50	423/21671	5.16558344529769e-06	0.000480740235700081	0.000275990088668866	HIF1A/EGF/DAPK1/RPS6KB1/KRAS/MAPK8/STAT3/FOXO4	8
group_G5_6_0	C0751688	Malignant Squamous Cell Neoplasm	6/50	193/21671	5.29537829450397e-06	0.000480740235700081	0.000275990088668866	HIF1A/KEAP1/EGF/DAPK1/KRAS/STAT3	6
group_G5_6_0	C0153452	Malignant neoplasm of gallbladder	8/50	425/21671	5.34730796795928e-06	0.000480740235700081	0.000275990088668866	HIF1A/KEAP1/TGM2/EGF/KRAS/MAPK8/AKT1S1/STAT3	8
group_G5_6_0	C0221023	Cyclic neutropenia	4/50	52/21671	6.25503261767687e-06	0.000544774247045795	0.000312751630883843	KEAP1/PRKAB1/KRAS/MAPK8	4
group_G5_6_0	C2145472	Urothelial Carcinoma	8/50	449/21671	7.98771863300276e-06	0.000674599146369051	0.00038728332766074	HIF1A/EGF/DAPK1/RPS6KB1/KRAS/STAT3/HDAC5/HSPA1A	8
group_G5_6_0	C0206624	Hepatoblastoma	8/50	452/21671	8.38447611251748e-06	0.00068728043898783	0.000394563581765529	HIF1A/KEAP1/LAMTOR1/EGF/YY1/KRAS/STAT3/NFE2L1	8
group_G5_6_0	C0393642	Sepsis-Associated Encephalopathy	4/50	57/21671	9.04949253496756e-06	0.000714417492853283	0.000410142801781576	USP8/DNM1L/STAT3/SIRT3	4
group_G5_6_0	C0553723	Squamous cell carcinoma of skin	8/50	458/21671	9.22821304008546e-06	0.000714417492853283	0.000410142801781576	HIF1A/EGF/DAPK1/USP8/DNM1L/KRAS/MAPK8/STAT3	8
group_G5_6_0	C0333641	Atrophic	4/50	58/21671	9.70334604933471e-06	0.000730897984851239	0.000419604153484744	TGM2/DAPK1/RPS6KB1/STAT3	4
group_G5_6_0	C0853897	Diabetic Cardiomyopathies	6/50	220/21671	1.1190955020079e-05	0.00080981378478634	0.000464909241355631	KEAP1/EGF/PRKAB1/MAPK8/STAT3/SIRT3	6
group_G5_6_0	C0740447	Diabetic peripheral neuropathy	5/50	129/21671	1.18180165643062e-05	0.00080981378478634	0.000464909241355631	HIF1A/RPS6KB1/PRKAB1/MAPK8/STAT3	5
group_G5_6_0	C1306837	Papillary Renal Cell Carcinoma	6/50	223/21671	1.20863230250583e-05	0.00080981378478634	0.000464909241355631	HIF1A/KEAP1/TGM2/EGF/DAPK1/FLCN	6
group_G5_6_0	C0004763	Barrett Esophagus	8/50	478/21671	1.25786293334512e-05	0.00080981378478634	0.000464909241355631	HIF1A/KEAP1/TGM2/EGF/DAPK1/KRAS/MAPK8/STAT3	8
group_G5_6_0	C4552091	Polyarthritis, Juvenile, Rheumatoid Factor Negative	5/50	131/21671	1.27343320014629e-05	0.00080981378478634	0.000464909241355631	EGF/EGR1/DAPK1/KRAS/STAT3	5
group_G5_6_0	C4704862	Polyarthritis, Juvenile, Rheumatoid Factor Positive	5/50	131/21671	1.27343320014629e-05	0.00080981378478634	0.000464909241355631	EGF/EGR1/DAPK1/KRAS/STAT3	5
group_G5_6_0	C0007112	Adenocarcinoma of prostate	7/50	342/21671	1.27850041372799e-05	0.00080981378478634	0.000464909241355631	HIF1A/TGM2/EGF/EGR1/KRAS/STAT3/RAB8A	7
group_G5_6_0	C0036220	Kaposi Sarcoma	8/50	488/21671	1.46063065590818e-05	0.000899348763511434	0.000516310736138606	HIF1A/EGF/EGR1/RPS6KB1/KRAS/MAPK8/STAT3/HDAC5	8
group_G5_6_0	C0333516	Tumor necrosis	7/50	350/21671	1.48439336639849e-05	0.000899348763511434	0.000516310736138606	HIF1A/EGF/PRKAB1/KRAS/MAPK8/STAT3/RAB8A	7
group_G5_6_0	C0034067	Pulmonary Emphysema	7/50	352/21671	1.53994602183238e-05	0.000913155226137625	0.000524236943602512	HIF1A/KEAP1/EGF/EGR1/DNM1L/STAT3/FLCN	7
group_G5_6_0	C3714758	Juvenile psoriatic arthritis	5/50	138/21671	1.638614354578e-05	0.00095142045962685	0.000546204784859332	EGF/EGR1/DAPK1/KRAS/STAT3	5
group_G5_6_0	C0235782	Gallbladder Carcinoma	8/50	498/21671	1.69030788151667e-05	0.000961405727711622	0.000551937267434014	HIF1A/KEAP1/TGM2/EGF/KRAS/MAPK8/AKT1S1/STAT3	8
group_G5_6_0	C0041956	Ureteral obstruction	7/50	359/21671	1.74813150250515e-05	0.00097440849949637	0.000559402080801648	HIF1A/KEAP1/TGM2/EGF/PRKAB1/MAPK8/STAT3	7
group_G5_6_0	C0007621	Neoplastic Cell Transformation	5/50	143/21671	1.94594333795103e-05	0.00106340080056265	0.000610492027592481	HIF1A/EGF/KRAS/MAPK8/STAT3	5
group_G5_6_0	C0740392	Infarction, Middle Cerebral Artery	5/50	145/21671	2.08072944407232e-05	0.00111519095396722	0.000640224444329944	HIF1A/BNIP3L/EGR1/STAT3/HDAC5	5
group_G5_6_0	C3888391	Nonnuclear polymorphic congenital cataract	4/50	71/21671	2.17372425057224e-05	0.00114305084648016	0.000656218641682185	EGF/KRAS/STAT3/ATF4	4
group_G5_6_0	C4728046	Diabetic wound	4/50	72/21671	2.29769009870001e-05	0.00118586338982906	0.000680797066281484	HIF1A/KEAP1/EGF/SIRT3	4
group_G5_6_0	C0334463	Malignant Fibrous Histiocytoma	5/50	150/21671	2.44960266501311e-05	0.00124128047770755	0.000712611684367451	HIF1A/KEAP1/EGF/KRAS/STAT3	5
group_G5_6_0	C3267003	Vascular endothelial growth factor overexpression	3/50	26/21671	2.8943673626102e-05	0.00144046461421333	0.000826962103602914	HIF1A/AKT1S1/STAT3	3
group_G5_6_0	C0162770	Right Ventricular Hypertrophy	5/50	160/21671	3.33867853997708e-05	0.00163243808612563	0.000937172923502337	HIF1A/KEAP1/PRKAB1/MAPK8/HDAC5	5
group_G5_6_0	C0018553	Hamartoma Syndrome, Multiple	6/50	270/21671	3.55000940514664e-05	0.00170584072623167	0.000979312939350797	HIF1A/TGM2/EGF/USP8/MAPK8/STAT3	6
group_G5_6_0	C0887833	Carcinoma, Pancreatic Ductal	4/50	82/21671	3.84065269893192e-05	0.00181422018168191	0.00104153293530357	HIF1A/KRAS/STAT3/HSPA1A	4
group_G5_6_0	C1519689	Tumor Promotion	5/50	170/21671	4.46001810451542e-05	0.00207167840954741	0.00118933816120411	HIF1A/KEAP1/EGF/MAPK8/STAT3	5
group_G5_6_0	C0087031	Juvenile-Onset Still Disease	5/50	171/21671	4.58641977859057e-05	0.00209546752834949	0.00120299535176146	EGF/EGR1/DAPK1/KRAS/STAT3	5
group_G5_6_0	C0019562	Von Hippel-Lindau Syndrome	5/50	174/21671	4.98233218249131e-05	0.00219530375025168	0.00126031072852626	HIF1A/TGM2/DAPK1/SEC13/FLCN	5
group_G5_6_0	C1827293	Carcinoma of urinary bladder, invasive	6/50	287/21671	4.98789191658303e-05	0.00219530375025168	0.00126031072852626	HIF1A/EGF/EGR1/STAT3/FOXO4/HSPA1A	6
group_G5_6_0	C1960398	HER2-positive carcinoma of breast	6/50	288/21671	5.08514554384203e-05	0.00219530375025168	0.00126031072852626	EGF/PRKAB1/KRAS/MAPK8/STAT3/ATF4	6
group_G5_6_0	C0162534	Prion Diseases	5/50	175/21671	5.12001233463793e-05	0.00219530375025168	0.00126031072852626	HIF1A/PRKAB1/DNM1L/AKT1S1/SIRT3	5
group_G5_6_0	C0022679	Cystic kidney	4/50	89/21671	5.29817072299002e-05	0.00223727300075351	0.00128440502375516	HIF1A/EGF/USP8/STAT3	4
group_G5_6_0	C0542476	Forgetful	7/50	429/21671	5.43543611788718e-05	0.00226097917321665	0.00129801459531634	EGR1/DAPK1/PRKAB1/KRAS/MAPK8/STAT3/ATF4	7
group_G5_6_0	C0011175	Dehydration	6/50	295/21671	5.80931568707269e-05	0.00235718108449539	0.00135324353612939	HIF1A/EGF/PRKAB1/STAT3/FOXO4/HSPA1A	6
group_G5_6_0	C0035222	Respiratory Distress Syndrome, Adult	7/50	434/21671	5.84678138520849e-05	0.00235718108449539	0.00135324353612939	HIF1A/EGF/DAPK1/MAPK8/STAT3/SIRT3/HSPA1A	7
group_G5_6_0	C0001339	Acute pancreatitis	7/50	435/21671	5.9320379817434e-05	0.00235718108449539	0.00135324353612939	HIF1A/EGF/EGR1/RAB7A/MAPK8/STAT3/HSPA1A	7
group_G5_6_0	C0270952	Muscular Dystrophy, Oculopharyngeal	3/50	33/21671	6.00501819157418e-05	0.00235718108449539	0.00135324353612939	TGM2/OPTN/PRKAB1	3
group_G5_6_0	C3811653	Experimental Organism Basal Cell Carcinoma	7/50	437/21671	6.10561256355373e-05	0.00236338086314226	0.00135680279190083	HIF1A/EGF/PRKAB1/KRAS/STAT3/SIRT3/ATF4	7
group_G5_6_0	C0005699	Blast Phase	6/50	299/21671	6.25879973946828e-05	0.00238417911751169	0.00136874294510897	DAPK1/RPS6KB1/YY1/PIK3R4/KRAS/MAPK8	6
group_G5_6_0	C0026918	Mycobacterium Infections	5/50	183/21671	6.33043612112899e-05	0.00238417911751169	0.00136874294510897	HIF1A/OPTN/CAMKK2/STAT3/SIRT3	5
group_G5_6_0	C0677936	Refractory cancer	5/50	184/21671	6.49602549542707e-05	0.0024139230741007	0.00138581877235778	HIF1A/TGM2/KRAS/STAT3/ATF4	5
group_G5_6_0	C1266042	Chromophobe Renal Cell Carcinoma	5/50	185/21671	6.66494013500783e-05	0.00244410370477195	0.0014031452915806	HIF1A/KEAP1/TGM2/DAPK1/FLCN	5
group_G5_6_0	C3495559	Juvenile arthritis	7/50	450/21671	7.33830021327038e-05	0.00265608346680319	0.00152484160275748	HIF1A/TGM2/EGF/EGR1/DAPK1/KRAS/STAT3	7
group_G5_6_0	C0019151	Hepatic Encephalopathy	4/50	100/21671	8.35165964081483e-05	0.0029463386606267	0.00169147537029161	HIF1A/TGM2/PRKDC/DNM1L	4
group_G5_6_0	C0340629	Aortic aneurysm without mention of rupture NOS	4/50	100/21671	8.35165964081483e-05	0.0029463386606267	0.00169147537029161	EGF/EGR1/STAT3/FOXO4	4
group_G5_6_0	C0013295	Duodenal Ulcer	4/50	102/21671	9.02038152544883e-05	0.003036195180109	0.00174306145969659	EGF/EGR1/STAT3/HSPA1A	4
group_G5_6_0	C0023283	Leishmaniasis, Cutaneous	4/50	102/21671	9.02038152544883e-05	0.003036195180109	0.00174306145969659	HIF1A/EGF/YY1/ATF4	4
group_G5_6_0	C0278660	Adult Synovial Sarcoma	5/50	198/21671	9.18483792235341e-05	0.003036195180109	0.00174306145969659	EGR1/VAMP3/MAPK8/STAT3/NEDD4	5
group_G5_6_0	C0279982	Childhood Synovial Sarcoma	5/50	198/21671	9.18483792235341e-05	0.003036195180109	0.00174306145969659	EGR1/VAMP3/MAPK8/STAT3/NEDD4	5
group_G5_6_0	C2713368	Hematopoetic Myelodysplasia	3/50	38/21671	9.20978051737382e-05	0.003036195180109	0.00174306145969659	EGR1/DAPK1/KRAS	3
group_G5_6_0	C0280321	Squamous cell carcinoma of the hypopharynx	4/50	103/21671	9.36895534586919e-05	0.003036195180109	0.00174306145969659	HIF1A/DAPK1/MAPK8/STAT3	4
group_G5_6_0	C3544205	Ovarian clear cell carcinoma	4/50	103/21671	9.36895534586919e-05	0.003036195180109	0.00174306145969659	HIF1A/EGF/KRAS/STAT3	4
group_G5_6_0	C0345905	Intrahepatic Cholangiocarcinoma	7/50	470/21671	9.62702459687426e-05	0.00308396753465386	0.00177048728218377	HIF1A/KEAP1/DAPK1/KRAS/MAPK8/STAT3/SIRT3	7
group_G5_6_0	C0020473	Hyperlipidemia	7/50	472/21671	9.88477485727772e-05	0.00313055312809466	0.00179723179223231	HIF1A/TGM2/PRKAB1/NEDD4/SIRT3/RAB8A/ATF4	7
group_G5_6_0	C0029172	Oral Submucous Fibrosis	4/50	106/21671	0.000104734794209144	0.00327297515122279	0.00187899542230228	HIF1A/TGM2/EGF/EGR1	4
group_G5_6_0	C0333983	Hyperplastic Polyp	5/50	204/21671	0.000105693492504503	0.00327297515122279	0.00187899542230228	HIF1A/EGF/KRAS/STAT3/HDAC5	5
group_G5_6_0	C0340803	Capillary malformation (disorder)	3/50	40/21671	0.000107512538458015	0.00329041758200119	0.00188900901729527	EGF/MAPK8/STAT3	3
group_G5_6_0	C0280217	stage, non-small cell lung cancer	4/50	107/21671	0.000108618018494478	0.00329041758200119	0.00188900901729527	HIF1A/KRAS/STAT3/NIPSNAP2	4
group_G5_6_0	C3900098	Adult Myelodysplastic Syndrome	6/50	332/21671	0.00011130190215376	0.00332763510203862	0.00191037537253742	HIF1A/EGR1/DAPK1/KRAS/MAPK8/STAT3	6
group_G5_6_0	C0279680	Transitional cell carcinoma of bladder	6/50	333/21671	0.000113146750706501	0.00332763510203862	0.00191037537253742	HIF1A/KRAS/MAPK8/STAT3/FLCN/HSPA1A	6
group_G5_6_0	C0007965	Chediak-Higashi Syndrome	3/50	41/21671	0.000115812166341745	0.00332763510203862	0.00191037537253742	PRKAB1/RAB7A/PIK3R4	3
group_G5_6_0	C1860224	ABLEPHARON-MACROSTOMIA SYNDROME	3/50	41/21671	0.000115812166341745	0.00332763510203862	0.00191037537253742	HIF1A/FOXO4/TRIM23	3
group_G5_6_0	C2347761	Childhood Myelodysplastic Syndrome	6/50	335/21671	0.000116909461839011	0.00332763510203862	0.00191037537253742	HIF1A/EGR1/DAPK1/KRAS/MAPK8/STAT3	6
group_G5_6_0	C0079772	T-Cell Lymphoma	7/50	485/21671	0.000117010491567917	0.00332763510203862	0.00191037537253742	HIF1A/EGR1/YY1/PRKAB1/KRAS/MAPK8/STAT3	7
group_G5_6_0	C1282496	Metastasis from malignant tumor of prostate	6/50	342/21671	0.000130870279847818	0.00368419666601888	0.00211507522986373	HIF1A/EGF/ULK1/KRAS/MAPK8/SIRT3	6
group_G5_6_0	C0011603	Dermatitis	7/50	496/21671	0.000134424655215059	0.00372776610966415	0.00214008818638774	HIF1A/TGM2/EGF/VAMP3/MAPK8/STAT3/HSPA1A	7
group_G5_6_0	C0031511	Pheochromocytoma	6/50	344/21671	0.000135093066765726	0.00372776610966415	0.00214008818638774	HIF1A/TGM2/EGF/RPS6KB1/DNM1L/MAPK8	6
group_G5_6_0	C0085183	Neoplasms, Second Primary	3/50	44/21671	0.000143186111279326	0.00391234992289688	0.00224605664751884	DAPK1/YY1/KRAS	3
group_G5_6_0	C0858252	Breast adenocarcinoma	5/50	219/21671	0.000147347018196249	0.00397752217553461	0.0022834716472391	HIF1A/EGF/EGR1/KRAS/STAT3	5
group_G5_6_0	C0205644	Carcinoma, Granular Cell	4/50	116/21671	0.000148425657070542	0.00397752217553461	0.0022834716472391	EGF/DAPK1/KRAS/STAT3	4
group_G5_6_0	C0205643	Carcinoma, Cribriform	4/50	117/21671	0.000153419656800642	0.00407219603336561	0.00233782334172407	EGF/DAPK1/KRAS/STAT3	4
group_G5_6_0	C0014057	Japanese Encephalitis	4/50	119/21671	0.000163770842079366	0.00426569473715134	0.00244890978810267	RAB5A/KRAS/NEDD4/ATF4	4
group_G5_6_0	C1856689	FRIEDREICH ATAXIA 1	4/50	119/21671	0.000163770842079366	0.00426569473715134	0.00244890978810267	HIF1A/DNM1L/SIRT3/ATF4	4
group_G5_6_0	C0007786	Brain Ischemia	6/50	358/21671	0.000167776686096576	0.00432957059399221	0.0024855805347641	HIF1A/EGR1/DNM1L/MAPK8/STAT3/HSPA1A	6
group_G5_6_0	C1510420	Cavitation	3/50	47/21671	0.000174455187669598	0.00446061108289146	0.00256081009423263	HIF1A/LAMTOR1/EGF	3
group_G5_6_0	C0936223	Metastatic Prostate Carcinoma	6/50	362/21671	0.000178180536354374	0.00450049913856146	0.00258370958797931	HIF1A/EGF/ULK1/KRAS/MAPK8/SIRT3	6
group_G5_6_0	C0750974	Brain Tumor, Primary	4/50	122/21671	0.000180231759233392	0.00450049913856146	0.00258370958797931	TGM2/OPTN/DAPK1/ATF4	4
group_G5_6_0	C0037286	Skin Neoplasms	6/50	363/21671	0.000180859671158552	0.00450049913856146	0.00258370958797931	HIF1A/EGF/DNM1L/KRAS/STAT3/FLCN	6
group_G5_6_0	C0034494	Rabies (disorder)	4/50	123/21671	0.00018597486123662	0.0045465959497058	0.00261017349104028	RAB7A/RAB5A/STAT3/NEDD4	4
group_G5_6_0	C0205641	Adenocarcinoma, Basal Cell	4/50	123/21671	0.00018597486123662	0.0045465959497058	0.00261017349104028	EGF/DAPK1/KRAS/STAT3	4
group_G5_6_0	C0086692	Benign Neoplasm	6/50	371/21671	0.000203460883311144	0.00493083027641878	0.00283076011563331	HIF1A/EGF/DAPK1/YY1/KRAS/STAT3	6
group_G5_6_0	C2347748	Adult Erythroleukemia	5/50	236/21671	0.000208629154312923	0.00501249528508721	0.00287764350776446	TGM2/EGR1/MAPK8/STAT3/RAB8A	5
group_G5_6_0	C4520840	Erythroleukemia (Erythroid/Myeloid)	5/50	237/21671	0.000212757688818298	0.00506799725415895	0.00290950685563485	TGM2/EGR1/MAPK8/STAT3/RAB8A	5
group_G5_6_0	C0016978	gallbladder neoplasm	3/50	51/21671	0.00022260400022018	0.00525760464926815	0.00301835932501939	KEAP1/EGF/KRAS	3
group_G5_6_0	C0920646	Ischemia of kidney	4/50	131/21671	0.000236786080252322	0.00554556979548926	0.00318367838994719	HIF1A/EGR1/DNM1L/SIRT3	4
group_G5_6_0	C0023892	Biliary cirrhosis	4/50	132/21671	0.000243772744999455	0.00563932867736608	0.0032375048022195	HIF1A/KEAP1/RPS6KB1/STAT3	4
group_G5_6_0	C0949664	Tauopathies	5/50	245/21671	0.000248073025150301	0.00563932867736608	0.0032375048022195	RPS6KB1/PRKAB1/DNM1L/MAPK8/HSPA1A	5
group_G5_6_0	C0279651	Gallbladder adenocarcinoma	3/50	53/21671	0.000249595596209208	0.00563932867736608	0.0032375048022195	HIF1A/KRAS/AKT1S1	3
group_G5_6_0	C0205645	Adenocarcinoma, Tubular	4/50	133/21671	0.000250906622172011	0.00563932867736608	0.0032375048022195	EGF/DAPK1/KRAS/STAT3	4
group_G5_6_0	C1849089	Broad forehead	4/50	133/21671	0.000250906622172011	0.00563932867736608	0.0032375048022195	WAC/YY1/KRAS/FLCN	4
group_G5_6_0	C0278595	Adult Fibrosarcoma	6/50	387/21671	0.000255344131406352	0.00566593894782495	0.00325278159903837	HIF1A/LAMTOR1/EGR1/MAPK8/ATF4/HSPA1A	6
group_G5_6_0	C0029401	Osteitis Deformans	4/50	134/21671	0.00025818953942367	0.00566593894782495	0.00325278159903837	KEAP1/OPTN/EGF/SMURF1	4
group_G5_6_0	C1266043	Sarcomatoid Renal Cell Carcinoma	4/50	134/21671	0.00025818953942367	0.00566593894782495	0.00325278159903837	KEAP1/TGM2/DAPK1/FLCN	4
group_G5_6_0	C1257763	Overnutrition	3/50	54/21671	0.000263849328935727	0.00569455553376116	0.00326921020955072	RPS6KB1/PRKAB1/SIRT3	3
group_G5_6_0	C1266050	Poorly Differentiated Thyroid Carcinoma	3/50	54/21671	0.000263849328935727	0.00569455553376116	0.00326921020955072	EGF/MAPK8/STAT3	3
group_G5_6_0	C0205642	Adenocarcinoma, Oxyphilic	4/50	135/21671	0.000265623329525996	0.00569455553376116	0.00326921020955072	EGF/DAPK1/KRAS/STAT3	4
group_G5_6_0	C1998028	Photoreceptor degeneration	4/50	136/21671	0.000273209830267305	0.00577526451035818	0.00331554474939831	HIF1A/PRKAB1/DNM1L/RAB8A	4
group_G5_6_0	C0220650	Metastatic malignant neoplasm to brain	6/50	392/21671	0.00027353244182536	0.00577526451035818	0.00331554474939831	HIF1A/EGF/EGR1/DAPK1/KRAS/STAT3	6
group_G5_6_0	C0266526	Norrie disease	3/50	55/21671	0.000278619099526889	0.00579486142075701	0.00332679521823151	KRAS/MAPK8/STAT3	3
group_G5_6_0	C1849157	Resistance to Insulin-Like Growth Factor I	3/50	55/21671	0.000278619099526889	0.00579486142075701	0.00332679521823151	HIF1A/KRAS/STAT3	3
group_G5_6_0	C0235989	Renal interstitial fibrosis	4/50	138/21671	0.000288848339301631	0.00596311349358257	0.00342338772505637	HIF1A/EGR1/MAPK8/STAT3	4
group_G5_6_0	C4721579	Secondary malignant neoplasm of colon and/or rectum	6/50	397/21671	0.000292726743253046	0.00597908930995214	0.00343255934550536	HIF1A/EGF/EGR1/YY1/KRAS/STAT3	6
group_G5_6_0	C0340100	High altitude pulmonary edema	3/50	56/21671	0.000293912893958896	0.00597908930995214	0.00343255934550536	HIF1A/DNM1L/HSPA1A	3
group_G5_6_0	C0206708	Cervical Intraepithelial Neoplasia	6/50	398/21671	0.000296689750800211	0.00599184301072601	0.0034398811686981	HIF1A/KEAP1/DAPK1/RAB5A/STAT3/SIRT3	6
group_G5_6_0	C0007873	Uterine Cervical Neoplasm	4/50	140/21671	0.000305119865365467	0.00611183034629822	0.00350876517907325	EGF/YY1/KRAS/STAT3	4
group_G5_6_0	C0376618	Endotoxemia	6/50	401/21671	0.000308832760099645	0.00611183034629822	0.00350876517907325	HIF1A/KEAP1/PRKAB1/STAT3/HDAC5/SIRT3	6
group_G5_6_0	C0342649	Vascular calcification	5/50	257/21671	0.00030920993140583	0.00611183034629822	0.00350876517907325	DAPK1/PRKAB1/NEDD4/ATF4/HSPA1A	5
group_G5_6_0	C4551687	Sarcoma of soft tissue	5/50	258/21671	0.000314776847031177	0.00617804980757669	0.00354678137499918	HIF1A/EGF/PRKDC/KRAS/STAT3	5
group_G5_6_0	C0006277	Bronchitis	3/50	58/21671	0.00032610419988789	0.00635561122438846	0.00364871832042394	KEAP1/RAB5A/MAPK8	3
group_G5_6_0	C0751690	Malignant Peripheral Nerve Sheath Tumor	5/50	261/21671	0.000331935038262445	0.00642432605303774	0.00368816709180495	HIF1A/EGF/KRAS/MAPK8/STAT3	5
group_G5_6_0	C0009171	Cocaine Abuse	4/50	144/21671	0.000339621530321981	0.0064830493493655	0.00372187978435048	EGR1/SMURF1/PRKAB1/HDAC5	4
group_G5_6_0	C0037772	Spastic Paraplegia	4/50	144/21671	0.000339621530321981	0.0064830493493655	0.00372187978435048	DAPK1/USP8/DNM1L/WDR45B	4
group_G5_6_0	C2826323	Refractory Cytopenia of Childhood	5/50	264/21671	0.000349793829199839	0.00663180545564593	0.00380727977360369	HIF1A/DAPK1/KRAS/STAT3/FLCN	5
group_G5_6_0	C0346302	Growth Hormone-Secreting Pituitary Adenoma	3/50	60/21671	0.000360485944788477	0.00671424820501632	0.00385460966201152	EGF/USP8/STAT3	3
group_G5_6_0	C0016057	Fibrosarcoma	6/50	413/21671	0.00036136965581358	0.00671424820501632	0.00385460966201152	HIF1A/LAMTOR1/EGR1/MAPK8/ATF4/HSPA1A	6
group_G5_6_0	C0023267	Fibroid Tumor	6/50	413/21671	0.00036136965581358	0.00671424820501632	0.00385460966201152	HIF1A/EGF/EGR1/DAPK1/KRAS/HSPA1A	6
group_G5_6_0	C0748355	Acute respiratory distress	4/50	147/21671	0.000367270571196048	0.00677869590677738	0.00389160870141507	HIF1A/EGF/DAPK1/STAT3	4
group_G5_6_0	C0020615	Hypoglycemia	6/50	420/21671	0.000395106918030391	0.00715287181276202	0.00410642084693909	HIF1A/KEAP1/TGM2/PRKAB1/DNM1L/MAPK8	6
group_G5_6_0	C0345967	Malignant mesothelioma	6/50	420/21671	0.000395106918030391	0.00715287181276202	0.00410642084693909	HIF1A/TGM2/EGF/DAPK1/YY1/STAT3	6
group_G5_6_0	C1167791	Skin toxicity	3/50	62/21671	0.000397119883793433	0.00715287181276202	0.00410642084693909	HIF1A/EGF/KRAS	3
group_G5_6_0	C0812413	Malignant Pleural Mesothelioma	6/50	421/21671	0.000400121444597886	0.00715287181276202	0.00410642084693909	HIF1A/TGM2/EGF/PRKAB1/KRAS/STAT3	6
group_G5_6_0	C0206699	Cystadenocarcinoma, Mucinous	2/50	13/21671	0.000400376032576561	0.00715287181276202	0.00410642084693909	EGF/KRAS	2
group_G5_6_0	C0006625	Cachexia	5/50	273/21671	0.000407762146120553	0.00723842739642027	0.00415553779485914	HIF1A/EGR1/PRKAB1/KRAS/STAT3	5
group_G5_6_0	C2750440	FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1	3/50	63/21671	0.000416300468794381	0.00725143379081213	0.00416300468794382	MAPK8/STAT3/SIRT3	3
group_G5_6_0	C2750441	LIVER DISEASE, ALCOHOLIC, SUSCEPTIBILITY TO, 1	3/50	63/21671	0.000416300468794381	0.00725143379081213	0.00416300468794382	MAPK8/STAT3/SIRT3	3
group_G5_6_0	C3150651	FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2	3/50	63/21671	0.000416300468794381	0.00725143379081213	0.00416300468794382	MAPK8/STAT3/SIRT3	3
group_G5_6_0	C0085413	Polycystic Kidney, Autosomal Dominant	5/50	280/21671	0.000457655529956135	0.00792227305582452	0.0045481294902473	HIF1A/EGF/PRKAB1/STAT3/HDAC5	5
group_G5_6_0	C3241937	Nonalcoholic Steatohepatitis	6/50	434/21671	0.000469966527627313	0.00800591760842204	0.0045961493266865	HIF1A/KEAP1/TGM2/RAB5A/MAPK8/SIRT3	6
group_G5_6_0	C0558353	Tongue Carcinoma	4/50	157/21671	0.000471105305985366	0.00800591760842204	0.0045961493266865	HIF1A/EGF/STAT3/SIRT3	4
group_G5_6_0	C1527390	Neoplasms, Intracranial	4/50	157/21671	0.000471105305985366	0.00800591760842204	0.0045961493266865	TGM2/DAPK1/RPS6KB1/MAPK8	4
group_G5_6_0	C3898127	Non-Metastatic Childhood Soft Tissue Sarcoma	4/50	160/21671	0.000505955691732146	0.00849456935456321	0.00487668136609298	HIF1A/PRKDC/KRAS/STAT3	4
group_G5_6_0	C4733095	HER2-negative breast cancer	4/50	160/21671	0.000505955691732146	0.00849456935456321	0.00487668136609298	EGF/MAPK8/STAT3/ATF4	4
group_G5_6_0	C0003130	Anoxia	5/50	287/21671	0.000512028155900591	0.00854504473350267	0.00490565897868829	HIF1A/BNIP3L/EGR1/STAT3/ATF4	5
group_G5_6_0	C1304508	Spindle cell hemangioma	3/50	68/21671	0.00052113844834008	0.00864531461621311	0.00496322331752457	HIF1A/PRKAB1/STAT3	3
group_G5_6_0	C0220613	Adult Soft Tissue Sarcoma	4/50	162/21671	0.000530186079927777	0.00869105315757607	0.00498948154005085	HIF1A/PRKDC/KRAS/STAT3	4
group_G5_6_0	C1266044	Collecting Duct Carcinoma of the Kidney	4/50	162/21671	0.000530186079927777	0.00869105315757607	0.00498948154005085	KEAP1/TGM2/DAPK1/FLCN	4
group_G5_6_0	C0085663	Plasmacytosis	2/50	15/21671	0.000537379810203827	0.00869105315757607	0.00498948154005085	TGM2/STAT3	2
group_G5_6_0	C0206740	Calcifying Odontogenic Cyst	2/50	15/21671	0.000537379810203827	0.00869105315757607	0.00498948154005085	HIF1A/KRAS	2
group_G5_6_0	C0003857	Congenital arteriovenous malformation	4/50	163/21671	0.00054260611748053	0.00869105315757607	0.00498948154005085	HIF1A/PIK3R4/KRAS/STAT3	4
group_G5_6_0	C0334583	Pilocytic Astrocytoma	4/50	163/21671	0.00054260611748053	0.00869105315757607	0.00498948154005085	HIF1A/KRAS/MAPK8/FLCN	4
group_G5_6_0	C3887551	Memory dysfunction	3/50	70/21671	0.000567380148499342	0.00903593413638667	0.00518747564342256	PRKAB1/STAT3/SIRT3	3
group_G5_6_0	C0162309	Adrenoleukodystrophy	5/50	294/21671	0.000571135494385939	0.0090440603571228	0.00519214085805399	HIF1A/PRKAB1/MAPK8/STAT3/ATF4	5
group_G5_6_0	C0220645	Childhood Soft Tissue Sarcoma	4/50	166/21671	0.000581108887138999	0.00915000264664627	0.00525296169165197	HIF1A/PRKDC/KRAS/STAT3	4
group_G5_6_0	C0031269	Peutz-Jeghers Syndrome	3/50	71/21671	0.00059145262964612	0.00915765821568743	0.00525735670796552	PRKAB1/KRAS/STAT3	3
group_G5_6_0	C0751075	Cancer of Digestive System	3/50	71/21671	0.00059145262964612	0.00915765821568743	0.00525735670796552	HIF1A/KRAS/STAT3	3
group_G5_6_0	C4049272	Tumour budding	3/50	71/21671	0.00059145262964612	0.00915765821568743	0.00525735670796552	DAPK1/KRAS/STAT3	3
group_G5_6_0	C0334233	Pleomorphic carcinoma	2/50	16/21671	0.000613243180032186	0.00923602986012661	0.00530234939942683	HIF1A/KRAS	2
group_G5_6_0	C0346010	Multiple fibrofolliculomas	2/50	16/21671	0.000613243180032186	0.00923602986012661	0.00530234939942683	HIF1A/FLCN	2
group_G5_6_0	C0519030	Pneumonia due to Klebsiella pneumoniae	2/50	16/21671	0.000613243180032186	0.00923602986012661	0.00530234939942683	MAPK8/SIRT3	2
group_G5_6_0	C0854750	Colorectal cancer recurrent	2/50	16/21671	0.000613243180032186	0.00923602986012661	0.00530234939942683	KRAS/STAT3	2
group_G5_6_0	C1838625	Warburg Sjo Fledelius syndrome	2/50	16/21671	0.000613243180032186	0.00923602986012661	0.00530234939942683	RAB7A/PIK3R4	2
group_G5_6_0	C0039101	synovial sarcoma	5/50	299/21671	0.000616398117683369	0.00923602986012661	0.00530234939942683	EGR1/VAMP3/MAPK8/STAT3/NEDD4	5
group_G5_6_0	C0206180	Ki-1+ Anaplastic Large Cell Lymphoma	5/50	300/21671	0.000625764965828888	0.00932624042655139	0.00535413874506	RPS6KB1/YY1/MAPK8/STAT3/HSPA1A	5
group_G5_6_0	C1512127	HER2 gene amplification	4/50	170/21671	0.000635418092847252	0.00936989536912852	0.00537920078600848	EGF/RPS6KB1/YY1/KRAS	4
group_G5_6_0	C4087504	Peritoneal dissemination	4/50	170/21671	0.000635418092847252	0.00936989536912852	0.00537920078600848	HIF1A/EGF/KRAS/STAT3	4
group_G5_6_0	C0023440	Acute Erythroblastic Leukemia	5/50	302/21671	0.000644819211337323	0.00945847969472168	0.00543005651652482	TGM2/EGR1/MAPK8/STAT3/RAB8A	5
group_G5_6_0	C0002448	Ameloblastoma	4/50	174/21671	0.000693238589367412	0.00996977047001399	0.00572358548691151	HIF1A/RPS6KB1/KRAS/STAT3	4
group_G5_6_0	C0025874	Metrorrhagia	2/50	17/21671	0.00069398474028802	0.00996977047001399	0.00572358548691151	USP8/STAT3	2
group_G5_6_0	C0268095	Keshan disease	2/50	17/21671	0.00069398474028802	0.00996977047001399	0.00572358548691151	HIF1A/STAT3	2
group_G5_6_0	C1827820	Fast acetylator due to N-acetyltransferase enzyme variant	2/50	17/21671	0.00069398474028802	0.00996977047001399	0.00572358548691151	EGF/KRAS	2
group_G5_6_1	C1836842	Psychomotor deterioration	3/10	13/21671	2.01868848867628e-08	2.15264300901423e-06	9.87450921566159e-07	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C2749688	Abnormal isoelectric focusing of serum transferrin	3/10	15/21671	3.20999344706124e-08	2.15264300901423e-06	9.87450921566159e-07	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1840319	Redundant neck skin	3/10	16/21671	3.94980368626464e-08	2.15264300901423e-06	9.87450921566159e-07	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C4073184	Thick hair	3/10	16/21671	3.94980368626464e-08	2.15264300901423e-06	9.87450921566159e-07	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C3840083	Late closure of anterior fontanel	3/10	21/21671	9.36942124492426e-08	4.08506766278698e-06	1.87388424898485e-06	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C4024890	Excessive wrinkled skin	3/10	25/21671	1.61870546540085e-07	5.88129652428977e-06	2.69784244233476e-06	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0426429	Broad nasal tip	4/10	125/21671	2.15653771734492e-07	6.71607460544562e-06	3.0807681676356e-06	ATP6V0A2/KPTN/ATP6V1E1/ATP6V1A	4
group_G5_6_1	C1836308	Generalized joint laxity	3/10	44/21671	9.27808482546589e-07	2.52827811493946e-05	1.15976060318324e-05	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0277959	Coarse hair	3/10	60/21671	2.38799631009977e-06	5.78425772890832e-05	2.65332923344419e-05	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1837108	Decreased muscle mass	3/10	65/21671	3.04445413881518e-06	6.61394696999981e-05	3.03392062844028e-05	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1850456	Progressive microcephaly	3/10	67/21671	3.33731269128431e-06	6.61394696999981e-05	3.03392062844028e-05	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0010495	Cutis Laxa	3/10	70/21671	3.81069952295615e-06	6.92277080003701e-05	3.17558293579679e-05	ATP6V0A2/ATP6V1E1/ATP6V0A4	3
group_G5_6_1	C1142533	Smooth philtrum	3/10	105/21671	1.2939537182537e-05	0.000216986085061005	9.95349014041309e-05	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1837770	Sparse hair	3/10	112/21671	1.57055912420538e-05	0.000228254592717849	0.000104703941613692	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C3161330	Profound intellectual disabilities	3/10	112/21671	1.57055912420538e-05	0.000228254592717849	0.000104703941613692	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1860834	Infantile muscular hypotonia	3/10	118/21671	1.83659572417225e-05	0.000243546376823744	0.000111718521478782	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1859778	Postnatal growth retardation	3/10	121/21671	1.98008946234042e-05	0.000243546376823744	0.000111718521478782	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0423110	Downward slant of palpebral fissure	4/10	391/21671	2.01093338661807e-05	0.000243546376823744	0.000111718521478782	ATP6V0A2/KPTN/ATP6V1E1/ATP6V1A	4
group_G5_6_1	C0022797	Adult Neuronal Ceroid Lipofuscinosis	2/10	16/21671	2.29186581201133e-05	0.000261431011077611	0.000119922482145693	CLCN3/CLCN6	2
group_G5_6_1	C0266483	Pachygyria	3/10	129/21671	2.39844964291386e-05	0.000261431011077611	0.000119922482145693	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C3665335	Cutis laxa, autosomal recessive	2/10	17/21671	2.59680858324022e-05	0.000269573462450652	0.000123657551582868	ATP6V0A2/ATP6V1A	2
group_G5_6_1	C0010964	Dandy-Walker Syndrome	3/10	137/21671	2.87128483791296e-05	0.000276830672014218	0.000126986546795513	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0014390	Entropion	2/10	18/21671	2.92069057629679e-05	0.000276830672014218	0.000126986546795513	ATP6V1E1/ATP6V1A	2
group_G5_6_1	C0022340	Late-Infantile Neuronal Ceroid Lipfuscinosis	2/10	19/21671	3.2634977496399e-05	0.000296434378925624	0.000135979072901662	CLCN3/CLCN6	2
group_G5_6_1	C4551649	Congenital Dysplasia Of The Hip	3/10	147/21671	3.54377237561535e-05	0.000309016951153659	0.000141750895024614	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0271183	Severe myopia	3/10	184/21671	6.91609629420478e-05	0.000579888073898709	0.000266003703623261	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1858085	Malar flattening	3/10	190/21671	7.60781871018293e-05	0.000614260918081436	0.000281771063340108	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1836996	Disproportionate tall stature	2/10	30/21671	8.27942949325873e-05	0.000644612724832287	0.000295693910473526	ATP6V1E1/ATP6V1A	2
group_G5_6_1	C0266464	Polymicrogyria	3/10	199/21671	8.72811585625151e-05	0.000656113536780286	0.000300969512284535	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1848207	Poor speech	3/10	208/21671	9.95143805553889e-05	0.000723137832035826	0.000331714601851296	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0019294	Hernia, Inguinal	3/10	225/21671	0.000125580846511454	0.000840550506986479	0.000385573627058018	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0023787	Lipodystrophy	3/10	226/21671	0.000127239296929146	0.000840550506986479	0.000385573627058018	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0266470	Cerebellar Hypoplasia	3/10	226/21671	0.000127239296929146	0.000840550506986479	0.000385573627058018	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0085615	Right bundle branch block	2/10	39/21671	0.000140723653824666	0.0009022869568758	0.000413893099484312	ATP6V1E1/ATP6V1A	2
group_G5_6_1	C1854114	Short nose	3/10	265/21671	0.000203593078001788	0.00126809402869685	0.000581694508576536	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0431663	Bilateral Cryptorchidism	2/10	48/21671	0.000213744871036028	0.00129434394127373	0.000593735752877856	ATP6V1E1/ATP6V1A	2
group_G5_6_1	C0027877	Neuronal Ceroid-Lipofuscinoses	2/10	51/21671	0.000241421540229918	0.00134110617959172	0.000615186320913634	CLCN3/CLCN6	2
group_G5_6_1	C1865014	Long philtrum	3/10	282/21671	0.000244496074587824	0.00134110617959172	0.000615186320913634	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0001126	Renal tubular acidosis	2/10	52/21671	0.000251016593262665	0.00134110617959172	0.000615186320913634	ATP6V0A2/ATP6V0A4	2
group_G5_6_1	C0751383	Juvenile Neuronal Ceroid Lipofuscinosis	2/10	52/21671	0.000251016593262665	0.00134110617959172	0.000615186320913634	CLCN3/CLCN6	2
group_G5_6_1	C0009081	Congenital clubfoot	3/10	285/21671	0.00025222639157459	0.00134110617959172	0.000615186320913634	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0011334	Dental caries	3/10	330/21671	0.000387845849008005	0.00201310464485108	0.000923442497638108	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1854301	Motor delay	3/10	384/21671	0.000603871561473382	0.00306148838142319	0.00140435246854275	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0520947	Clumsiness - motor delay	3/10	393/21671	0.000646028893261793	0.00320077951661525	0.00146824748468589	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0232466	Feeding difficulties	3/10	473/21671	0.00110592897643338	0.00528316280122769	0.00242346917487509	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C4553743	Spasticity, CTCAE	3/10	477/21671	0.00113317531398927	0.00528316280122769	0.00242346917487509	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C1835884	Triangular face	2/10	111/21671	0.00113903051219129	0.00528316280122769	0.00242346917487509	ATP6V1E1/ATP6V1A	2
group_G5_6_1	C0239234	Low set ears	3/10	489/21671	0.00121747631245143	0.00552937158571689	0.0025364089842738	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0240635	Byzanthine arch palate	3/10	497/21671	0.00127583872919421	0.00567618046865997	0.00260375250855962	ATP6V0A2/ATP6V1E1/ATP6V1A	3
group_G5_6_1	C0600033	Acquired Kyphoscoliosis	2/10	149/21671	0.00203799653058303	0.00888566487334201	0.00407599306116606	ATP6V0A2/ATP6V1E1	2
group_G5_6_1	C0345392	Congenital kyphoscoliosis	2/10	151/21671	0.00209223152500721	0.00894326416571708	0.00410241475491609	ATP6V0A2/ATP6V1E1	2
group_G5_6_1	C0575158	Kyphoscoliosis deformity of spine	2/10	155/21671	0.00220275455294017	0.00923462485655686	0.00423606644796186	ATP6V0A2/ATP6V1E1	2
group_G5_6_2	C0085078	Lysosomal Storage Diseases	6/8	130/21671	1.15011355290923e-12	4.4739417208169e-10	1.70701064168633e-10	PPT2/IDS/ARSG/NAGLU/GALNS/GLA	6
group_G5_6_2	C0026703	Mucopolysaccharidoses	4/8	48/21671	1.47294845046433e-09	2.86488473615312e-07	1.09308279744984e-07	IDS/ARSG/NAGLU/GALNS	4
group_G5_6_2	C0026706	Mucopolysaccharidosis III	3/8	17/21671	2.23984996409798e-08	2.90433878678038e-06	1.10813629802742e-06	IDS/ARSG/NAGLU	3
group_G5_6_2	C0086651	Mucopolysaccharidosis, MPS-IV-A	3/8	19/21671	3.19068110681864e-08	3.10293737638113e-06	1.18391062121429e-06	IDS/NAGLU/GALNS	3
group_G5_6_2	C1845847	Coarse facial features	4/8	194/21671	4.23809904238087e-07	3.29724105497232e-05	1.25804624205411e-05	IDS/NAGLU/GALNS/GLA	4
group_G5_6_2	C0086647	Mucopolysaccharidosis Type IIIA	2/8	25/21671	3.56227244739088e-05	0.00230953997005842	0.000881193710670376	IDS/NAGLU	2
group_G5_6_2	C0026707	Mucopolysaccharidosis IV	2/8	28/21671	4.48597740589286e-05	0.00249292172984618	0.000951162126662998	IDS/GALNS	2
group_G5_6_2	C0086795	Pfaundler-Hurler Syndrome	2/8	36/21671	7.46559118274458e-05	0.00363014371260955	0.00138506362732498	IDS/NAGLU	2
group_G5_6_2	C0241654	Abnormal heart valve morphology	2/8	42/21671	0.000101916745544103	0.0044050682240729	0.00168073229493784	IDS/GALNS	2
group_G5_6_2	C0027877	Neuronal Ceroid-Lipofuscinoses	2/8	51/21671	0.000150671332767025	0.00468802584045679	0.00178869339332812	PPT2/ARSG	2
group_G5_6_2	C0342751	Generalized glycogen storage disease of infants	2/8	51/21671	0.000150671332767025	0.00468802584045679	0.00178869339332812	IDS/GLA	2
group_G5_6_2	C0037317	Sleep disturbances	3/8	311/21671	0.000155399545690259	0.00468802584045679	0.00178869339332812	IDS/SIAE/NAGLU	3
group_G5_6_2	C0581381	Recurrent upper respiratory tract infection	2/8	52/21671	0.000156669244025548	0.00468802584045679	0.00178869339332812	NAGLU/GALNS	2
group_G5_6_2	C0851578	Sleep Disorders	3/8	360/21671	0.000239295662724289	0.00664900091426774	0.0025368938679793	IDS/SIAE/NAGLU	3
group_G5_6_2	C0947785	[D]Sleep disturbances (& [hypersomnia] or [insomnia])	2/8	69/21671	0.000276314915730615	0.00711331197964801	0.00271404949027295	IDS/SIAE	2
group_G5_6_2	C1844813	Widely spaced teeth	2/8	71/21671	0.000292578384767013	0.00711331197964801	0.00271404949027295	IDS/GALNS	2
group_G5_6_9	C1325327	fibrinogen activity	1/2	26/21671	0.00239813597040606	0.0083934758964212	NA	TOMM7	1
group_G5_6_9	C1561955	Fibrinogen, CTCAE	1/2	26/21671	0.00239813597040606	0.0083934758964212	NA	TOMM7	1
group_G9_0	C0006023	Borna Disease	2/3	26/21671	4.14931068323318e-06	0.00178005428310704	0.000270797118274166	PARG/PARP1	2
group_G9_All	C0006023	Borna Disease	3/4	26/21671	6.12719885001137e-09	4.02556964445747e-06	9.41653718001748e-07	PARP1/MIF/PARG	3
group_G9_All	C3669246	Mammary adenocarcinoma	2/4	29/21671	1.03573254290953e-05	0.00194816812124138	0.000455711841226054	PARP1/MIF	2
group_G9_All	C3658301	Mycoplasma-Induced Stevens-Johnson Syndrome	2/4	30/21671	1.10964510646798e-05	0.00194816812124138	0.000455711841226054	PARP1/MIF	2
group_G9_All	C1274933	Drug-Induced Stevens Johnson Syndrome	2/4	31/21671	1.18609931278014e-05	0.00194816812124138	0.000455711841226054	PARP1/MIF	2
group_G9_All	C3658302	Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum	2/4	50/21671	3.12101545179772e-05	0.0041010143036622	0.00095930159149993	PARP1/MIF	2
group_G9_All	C0038325	Stevens-Johnson Syndrome	2/4	67/21671	5.62721596432893e-05	0.00560333561948765	0.00131072178233629	PARP1/MIF	2
group_G9_All	C0025281	Meniere Disease	2/4	69/21671	5.97006839214818e-05	0.00560333561948765	0.00131072178233629	PARP1/MIF	2
group_G9_All	C0036529	Myocardial Diseases, Secondary	2/4	101/21671	0.000128258339697303	0.00963717092051569	0.00225430898725513	PARP1/MIF	2
group_G9_All	C0520459	Necrotizing Enterocolitis	2/4	103/21671	0.000133397608985747	0.00963717092051569	0.00225430898725513	PARP1/MIF	2
group_G9_All	C0033141	Cardiomyopathies, Primary	2/4	108/21671	0.000146684488896738	0.00963717092051569	0.00225430898725513	PARP1/MIF	2
